

Independent Auditor's Report

To the Members of HealthCare Global Enterprises Limited

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of HealthCare Global Enterprises Limited (hereinafter referred to as the "Holding Company"), its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), and its joint venture, which comprise the consolidated balance sheet as at 31 March 2025, and the consolidated statement of profit and loss (including other comprehensive income), consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of the other auditors on separate/ consolidated financial statements/ financial information of such subsidiaries as were audited by the other auditors, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group and its joint venture as at 31 March 2025, of its consolidated profit and other comprehensive income, consolidated changes in equity and consolidated cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Group and its joint venture in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in terms of the Code of Ethics issued by the Institute of Chartered Accountants of India and the relevant provisions of the Act, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence obtained by us along with the consideration of reports of the other auditors referred to in paragraph (a) of the "Other Matters" section below, is sufficient and appropriate to provide a basis for our opinion on the consolidated financial statements.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment and based on the consideration of reports of other auditors on separate/consolidated financial statement of components audited by them, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter

Key audit matter	
The key audit matter	How the matter was addressed in our audit

V4.

Independent Auditor's Report (Continued)

HealthCare Global Enterprises Limited

<p>Impairment evaluation of goodwill</p> <p>Refer note 3(j), note 3(p)(ii), note 7, and note 7(A) to the consolidated financial statements.</p> <p>Goodwill is a significant item on the consolidated balance sheet for which the Holding Company performs impairment testing at least annually.</p> <p>In performing such impairment assessments, the Holding Company compares the carrying value of each of the identifiable Cash Generating Units ("CGUs") to which the goodwill has been allocated with its respective recoverable values, to determine whether any impairment loss should be recognised.</p> <p>The Holding Company's process of assessment of impairment of goodwill involves using key assumptions including estimates of revenue growth rate, profitability, discount rate and terminal growth rate. Any changes to these assumptions could result in different recoverable value.</p> <p>Due to the significance of the carrying amount of goodwill and significant judgments required to compute recoverable values, we have determined this to be a key audit matter.</p>	<p>In view of the significance of the matter, we applied the following audit procedures in this area, amongst others to obtain sufficient appropriate audit evidence:</p> <ul style="list-style-type: none"> • Assessed the appropriateness of accounting policy for impairment of goodwill as per relevant accounting standards. • Evaluated the design and implementation of key internal financial controls relating to impairment process and tested the operating effectiveness of such controls. • We assessed the adequacy of the level of impairment by: <ul style="list-style-type: none"> -evaluating with the help of our valuation specialists, where required, appropriateness of the valuation methodology and of key assumptions, specifically those relating to revenue growth rates, profitability, discount rates and terminal growth rates with reference to our understanding of their business and industry, historical trends and underlying business strategies and growth plans; - performing sensitivity analysis of the key assumptions. • Assessed the adequacy of disclosures in the consolidated financial statements in accordance with the relevant accounting standards.
---	---

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Holding Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the Annual report, but does not include the financial statements and auditor's reports thereon. The Annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the consolidated financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the Annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take necessary actions, as applicable under the relevant laws and regulations.

Management's and Board of Directors'/Designated Partners' Responsibilities for the Consolidated Financial Statements

The Holding Company's Management and Board of Directors are responsible for the preparation and presentation of these consolidated financial statements in term of the requirements of the Act that give

Vy.

Independent Auditor's Report (Continued)

HealthCare Global Enterprises Limited

a true and fair view of the consolidated state of affairs, consolidated profit/ loss and other comprehensive income, consolidated statement of changes in equity and consolidated cash flows of the Group including its joint venture in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. The respective Management and Board of Directors of the companies/ Designated Partners of the Limited Liability Partnerships (LLPs) included in the Group and of its joint venture are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of each company/LLP and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Management and Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Management and Board of Directors of the companies/ Designated Partners of the LLPs included in the Group and of its joint venture are responsible for assessing the ability of each company/LLP to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/Designated Partners either intends to liquidate the Company/LLP or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies/ Designated Partners of the LLPs included in the Group the respective Board of Directors of its joint venture are responsible for overseeing the financial reporting process of each company/LLP.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of consolidated financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the

V4.

Independent Auditor's Report (Continued)

HealthCare Global Enterprises Limited

consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its joint venture to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements of such entities or business activities within the Group and its joint venture to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the consolidated financial statements of which we are the independent auditors. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in paragraph (a) of the section titled "Other Matters" in this audit report.

We communicate with those charged with governance of the Holding Company and subsidiary companies incorporated in India and audited by us and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

- a. We did not audit the financial statements / financial information of 11 subsidiaries and 7 step down subsidiaries, whose financial statements/financial information reflects total assets (before consolidation adjustments) of Rs. 7,632.42 million as at 31 March 2025, total revenues (before consolidation adjustments) of Rs. 4,911.34 and net cash inflows (before consolidation adjustments) amounting to Rs. 95.01 million for the year ended on that date, as considered in the consolidated financial statements. The consolidated financial statements also include the Group's share of net profit (and other comprehensive income) of Rs. 7.70 million for the year ended 31 March 2025, in respect of a joint venture, whose financial statements/financial information has not been audited by us. These financial statements/ financial information have been audited by other auditors whose reports has been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and a joint venture, and our report in terms of sub-section (3) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiaries and a joint venture is based solely on the reports of the other auditors.
- b. Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

Vy.

Independent Auditor's Report (Continued)

HealthCare Global Enterprises Limited

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
- 2 A. As required by Section 143(3) of the Act, based on our audit and on the consideration of reports of the other auditors on separate/consolidated financial statements/ financial information of such subsidiaries and a joint venture as were audited by other auditors, as noted in the "Other Matters" paragraph, we report, to the extent applicable, that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
 - b. In our opinion, proper books of accounts as required by law relating to preparation of aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors, except for the matters stated in the paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - c. The consolidated balance sheet, the consolidated statement of profit and loss (including other comprehensive income), the consolidated statement of changes in equity and the consolidated statement of cash flows dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
 - d. In our opinion, the aforesaid consolidated financial statements comply with the Ind AS specified under Section 133 of the Act.
 - e. On the basis of the written representations received from the directors of the Holding Company and subsidiary companies incorporated in India and audited by us as on 01 April 2025 taken on record by the Board of Directors of the Holding Company and subsidiary companies incorporated in India and audited by us and the reports of the statutory auditors of its subsidiary companies incorporated in India, none of the directors of the Group companies incorporated in India is disqualified as on 31 March 2025 from being appointed as a director in terms of Section 164(2) of the Act.
 - f. the remarks relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2(A)(b) above on reporting under Section 143(3)(b) of the Act and paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - g. With respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies incorporated in India and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
- B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate/ consolidated financial statements/ financial information of the subsidiaries and a joint venture, as noted in the "Other Matters" paragraph:
 - a. The consolidated financial statements disclose the impact of pending litigations as at 31 March 2025 on the consolidated financial position of the Group and its joint venture. Refer Note 33 to the consolidated financial statements.
 - b. The Group and its joint venture did not have any material foreseeable losses on long-term contracts including derivative contracts during the year ended 31 March 2025.
 - c. There are no amounts which are required to be transferred to the Investor Education and

Independent Auditor's Report (Continued)

HealthCare Global Enterprises Limited

Protection Fund by the Holding Company or its subsidiary companies incorporated in India during the year ended 31 March 2025.

- d (i) The respective management of the Holding Company and its subsidiary companies incorporated in India whose financial statements/financial information have been audited have represented to us and the other auditors of such subsidiary companies that, to the best of its knowledge and belief, as disclosed in the Note 49(iv) to the consolidated financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company or any of such subsidiary companies incorporated in India to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company or any of such subsidiary companies incorporated in India ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (ii) The respective management of the Holding Company and its subsidiary companies incorporated in India whose financial statements/financial information have been audited have represented to us and the other auditors of such subsidiary companies that, to the best of its knowledge and belief, as disclosed in the Note 49(v) to the consolidated financial statements, no funds have been received by the Holding Company or any of such subsidiary companies incorporated in India from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Holding Company or any of such subsidiary companies incorporated in India shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us and that performed by the auditors of the subsidiary companies incorporated in India whose financial statements/financial information have been audited under the Act, nothing has come to our or other auditors notice that has caused us or other auditors to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.
- e. The Holding Company and its subsidiary companies incorporated in India has neither declared nor paid any dividend during the year.
- f. Based on our examination, which included test checks, and that performed by the respective auditors of the subsidiary companies which are companies incorporated in India whose financial statements have been audited under the Act, except for the instances mentioned below, the Holding Company and the subsidiary companies which are companies incorporated in India have used accounting softwares for maintaining its books of account which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective softwares:
- i. For the Holding Company and four subsidiary companies, the audit trail (edit log) feature was not enabled in the accounting software used for maintaining books of accounts relating to revenue and consumption for direct data changes at the database level from 1 April 2024 till 5 April 2024.
- ii. For the Holding Company and four subsidiary companies, the audit trail (edit log) feature was not enabled in another accounting software used for maintaining the general ledger and other records for: (a) direct data changes at the database and for changes made by users with privileged access rights; and (b) at the application level for certain tables for a part of the year (i.e. from 1 April 2024 to 15 May 2024) and for certain tables (relating to payroll masters) for the complete year.
- iii. In respect of two subsidiary companies and two step-down subsidiary companies (including one subsidiary and two step-down subsidiary companies acquired during the year), the feature of recording audit trail is not enabled in the respective accounting softwares used for maintaining

Independent Auditor's Report (Continued)

HealthCare Global Enterprises Limited

books of accounts.

Further, for the periods where audit trail (edit log) facility was enabled and operated for the respective accounting softwares, we did not come across any instance of the audit trail feature being tampered with. Additionally, except where the audit trail was not enabled in the previous year, the audit trail has been preserved by the Holding Company and its subsidiary companies incorporated in India, as per the statutory requirements for record retention.


C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us and based on the reports of the statutory auditors of such subsidiary companies incorporated in India which were not audited by us, the remuneration paid during the current year by the Holding Company and its subsidiary companies to its directors, where applicable, is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director by the Holding Company and its subsidiary companies is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248WW-100022



Vikash Gupta

Partner

Place: Bangalore

Date: 24 May 2025

Membership No.: 064597

ICAI UDIN:25064597BMOXRQ5137

Annexure A to the Independent Auditor's Report on the Consolidated Financial Statements of HealthCare Global Enterprises Limited for the year ended 31 March 2025

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

- (xxi) In our opinion and according to the information and explanations given to us, following companies incorporated in India and included in the consolidated financial statements, have unfavourable remarks, qualification or adverse remarks given by the respective auditor in his reports under the Companies (Auditor's Report) Order, 2020 (CARO):

Sr. No.	Name of the entities	CIN	Holding Company/Subsidiary/ JV/ Associate	Clause number of the CARO report which is unfavourable or qualified or adverse
1	HealthCare Global Enterprises Limited	L15200KA1998 PLC023489	Holding Company	i (c)

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Vikash Gupta

Partner

Place: Bangalore

Date: 24 May 2025

Membership No.: 064597

ICAI UDIN:25064597BMOXRQ5137

Annexure B to the Independent Auditor's Report on the consolidated financial statements of HealthCare Global Enterprises Limited for the year ended 31 March 2025

Report on the internal financial controls with reference to the aforesaid consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act

(Referred to in paragraph 2(A)(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

In conjunction with our audit of the consolidated financial statements of HealthCare Global Enterprises Limited (hereinafter referred to as "the Holding Company") as of and for the year ended 31 March 2025, we have audited the internal financial controls with reference to financial statements of the Holding Company and such companies incorporated in India under the Act which are its subsidiary companies, as of that date.

In our opinion and based on the consideration of reports of the other auditors on internal financial controls with reference to financial statements/financial information of subsidiary companies, as were audited by the other auditors, the Holding Company and such companies incorporated in India which are its subsidiary companies, have, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2025, based on the internal financial controls with reference to financial statements criteria established by such companies considering the essential components of such internal controls stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's and Board of Directors' Responsibilities for Internal Financial Controls

The respective Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the respective Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors

Vy.

Annexure B to the Independent Auditor's Report on the consolidated financial statements of HealthCare Global Enterprises Limited for the year ended 31 March 2025 (Continued)

of the relevant subsidiary companies in terms of their reports referred to in the Other Matter paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls with Reference to Financial Statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Other Matter

Our aforesaid report under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to financial statements/financial information insofar as it relates to six subsidiary and two step down subsidiary companies, which are companies incorporated in India, is based on the corresponding reports of the auditors of such companies incorporated in India.

Our opinion is not modified in respect of this matter.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Vikash Gupta

Partner

Place: Bangalore

Membership No.: 064597

Date: 24 May 2025

ICAI UDIN:25064597BMOXRQ5137

HealthCare Global Enterprises Limited
Consolidated Balance Sheet as at 31 March 2025

Particulars	Note No.	(Rs. in million)	
		As at 31 March 2025	As at 31 March 2024
ASSETS			
Non-current assets			
(a) Property, plant and equipment	5	12,689.18	10,146.94
(b) Capital work-in-progress	5	247.56	831.84
(c) Right-of-use assets	6	6,941.12	4,906.61
(d) Goodwill	7	4,299.50	2,229.35
(e) Other intangible assets	7	489.07	298.71
(f) Investments in equity accounted investee	8(A)	43.09	33.60
(g) Financial assets			
(i) Investments	8(B)	70.03	69.65
(ii) Other financial assets	10	704.69	486.15
(h) Deferred tax assets (net)	32.3	249.93	70.58
(i) Other tax assets (net)	32.4	855.38	769.69
(j) Other non-current assets	11	404.84	433.34
Total non current assets		26,994.39	20,276.46
Current assets			
(a) Inventories	12	530.23	426.68
(b) Financial assets			
(i) Trade receivables	13	4,008.96	2,940.26
(ii) Cash and cash equivalents	14	2,358.71	2,726.13
(iii) Bank balance other than cash and cash equivalents above	14.1	1,118.26	304.60
(iv) Loans	9	26.96	19.43
(v) Other financial assets	10	49.84	67.80
(c) Other current assets	11	345.01	313.62
Total current assets		8,437.97	6,798.52
TOTAL ASSETS		35,432.36	27,074.98
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	15	1,394.16	1,392.90
(b) Other equity	16	7,830.25	6,864.90
Equity attributable to owners of the Company		9,224.41	8,257.80
Non-controlling interests	17	676.05	393.38
Total equity		9,900.46	8,651.18
Liabilities			
Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	18	6,045.84	4,853.01
(ii) Lease liabilities	6	7,750.86	5,588.16
(iii) Other financial liabilities	19	634.00	-
(b) Provisions	21	214.34	156.62
(c) Deferred tax liabilities (net)	32.3	35.35	60.75
(d) Other non-current liabilities	20	387.33	328.21
Total non-current liabilities		15,067.72	10,986.75
Current liabilities			
(a) Financial Liabilities			
(i) Borrowings	18	3,976.47	1,874.56
(ii) Lease liabilities	6	599.04	427.87
(iii) Trade payables	22		
Total outstanding dues of micro enterprises and small enterprises		41.38	62.12
Total outstanding dues of creditors other than micro enterprises and small enterprises		3,301.21	2,748.53
(iv) Other financial liabilities	19	1,959.20	1,636.51
(b) Other current liabilities	20	366.97	482.62
(c) Provisions	21	193.54	182.86
(d) Current tax liabilities (net)	32.5	26.37	21.98
Total current liabilities		10,464.18	7,437.05
Total liabilities		25,531.90	18,423.80
TOTAL EQUITY AND LIABILITIES		35,432.36	27,074.98
Material accounting policies	3		

The accompanying notes are an integral part of these consolidated financial statements

As per our reports of even date attached
for BSR & Co. LLP
Chartered Accountants
Firm's registration number 101248W/W-100022

Vikash Gupta
Partner
Membership number 064597

Place Bengaluru
Date 24 May 2025

for and on behalf of the Board of Directors of
HealthCare Global Enterprises Limited

Dr. B.S. Ajaikumar
Executive Chairman
DIN 00713779
Place Bengaluru
Date 24 May 2025

Ruby Ritolia
Chief Financial Officer
Place Bengaluru
Date 24 May 2025

Meghraj Arvindrao Gore
Chief Executive Officer
Place Bengaluru
Date 24 May 2025

Sonu Mannel
Company Secretary
Place Bengaluru
Date 24 May 2025

Arijali Ajaikumar Rossi
Director
DIN 08057112
Place Geneva
Date 24 May 2025



HealthCare Global Enterprises Limited
Consolidated Statement of Profit and Loss for the year ended 31 March 2025

Particulars	Note No.	(Rs in million)	
		For the year ended 31 March 2025	For the year ended 31 March 2024
I Income			
Revenue from operations	23	22,181.36	19,078.71
Income from government grant	24	47.14	42.48
Other income	25	348.14	169.42
Total income (I)		22,576.64	19,290.61
II Expenses			
Purchases of medical and non-medical items		5,902.16	4,793.66
Changes in inventories	26	(96.17)	(39.49)
Employee benefits expense	27	3,534.75	3,082.42
Finance costs	28	1,545.61	1,087.36
Depreciation and amortisation expense	29	2,113.44	1,743.56
Other expenses	30	9,014.92	7,988.74
Total expenses (II)		22,014.71	18,656.25
III Profit before share of profit / (loss) of joint venture, exceptional items and tax (I-II)		561.93	634.36
IV Share of profit / (loss) of joint venture		7.71	3.88
V Profit before exceptional items and tax (III + IV)		569.64	638.24
VI Exceptional items, net gain	31	-	39.05
VII Profit before tax (V+VI)		569.64	677.29
VIII Tax expense			
(1) Current tax	32.1	286.63	343.15
(2) Deferred tax expense / (credit)	32.1	(205.33)	(79.20)
Total tax expense		81.30	263.95
IX Profit for the year (VII-VIII)		488.34	413.34
X Other comprehensive income / (loss)			
(i) Items that will not be reclassified subsequently to profit or loss			
(a) Remeasurements of the defined benefit plans	37.2	4.06	(7.97)
(b) Income tax on the above	32.2	(2.86)	1.55
(ii) Items that will be reclassified to profit or loss			
(a) Exchange differences on translation of financial statements of foreign operations		16.81	1.79
(b) Income tax on the above	32.2	-	-
Other comprehensive income / (loss) for the year, net of tax		18.01	(4.63)
XI Total comprehensive income for the year (IX+X)		506.35	408.71
Profit / (loss) for the year attributable to:			
Owners of the Company		444.10	481.55
Non - controlling interests		44.24	(68.21)
		488.34	413.34
Other comprehensive income / (loss) for the year attributable to:			
Owners of the Company		16.14	(4.28)
Non-controlling interests		1.87	(0.35)
		18.01	(4.63)
Total comprehensive income / (loss) for the year attributable to:			
Owners of the Company		460.24	477.27
Non controlling interests		46.11	(68.56)
		506.35	408.71
Earnings per share (equity share of Rs. 10/- each):			
Basic (in Rs)	35.1	3.19	3.46
Diluted (in Rs)	35.2	3.14	3.43
Material accounting policies	3		

The accompanying notes are an integral part of these consolidated financial statements

As per our reports of even date attached
for **BSR & Co. LLP**
Chartered Accountants
Firm's registration number 101248W/W-100022

Vikash Gupta
Partner
Membership number 064597

for and on behalf of the Board of Directors of
HealthCare Global Enterprises Limited

Dr. B. S. Ajal Kumar
Executive Chairman
DIN 00713779
Place Bengaluru
Date 24 May 2025

Meghraj Arvindrao Gore
Chief Executive Officer
Place Bengaluru
Date 24 May 2025

Anjali Ajaikumar Rossi
Director
DIN 08057112
Place Geneva
Date 24 May 2025

Ruby Bitolia
Chief Financial Officer
Place Bengaluru
Date 24 May 2025

Syru Manuel
Company Secretary
Place Bengaluru
Date 24 May 2025



Place Bengaluru
Date 24 May 2025

HealthCare Global Enterprises Limited

Consolidated Cash Flow Statement for the year ended 31 March 2025

Rs. in million

Particulars	Note No.	For the year ended 31 March 2025	For the year ended 31 March 2024
Cash flows from operating activities			
Profit before tax		569.64	677.29
Adjustments for:			
Finance costs		1,545.61	1,087.36
Gain on investment revalued at FVTPL		(1.57)	(2.17)
Loss on disposal of property, plant and equipment (net)		10.64	17.74
Trade receivable written off (net)		97.27	4.32
Loss allowance on trade receivables		106.97	225.61
Remeasurement of contingent consideration		(27.82)	-
Interest income		(158.82)	(126.97)
Net gain on termination of lease		(10.24)	(17.57)
Depreciation and amortisation expense		2,113.44	1,743.56
Payables no longer required written back		-	(6.41)
Income from government grant		(47.14)	(42.48)
Expenses on employee stock option scheme		65.44	78.46
Net foreign exchange (gain)		(0.79)	(4.46)
Share of (profit) of equity accounted investee		(7.76)	(3.88)
Exceptional items	31	-	(39.05)
Movements in working capital:			
Changes in trade receivables		(907.51)	(278.17)
Changes in inventories		(96.13)	(39.51)
Changes in loans, financial assets and other assets		(101.78)	(79.20)
Changes in trade payables, financial liabilities and other liabilities		295.10	99.38
Changes in provisions		45.36	25.62
Cash generated from operations		3,489.91	3,319.47
Income taxes paid (net of refunds)		(318.82)	(473.68)
Net cash generated from operating activities (A)		3,171.09	2,845.79
Cash flows from investing activities			
Fixed deposits invested		(1,179.00)	(265.70)
Proceeds from maturity of fixed deposits		252.18	250.50
Acquisition of property, plant and equipment and others		(2,088.67)	(1,856.80)
Proceeds from disposal of property, plant and equipment		15.44	17.01
Payment for acquisition of business (net of cash acquired)	45.1 & 45.2	(1,971.95)	(450.00)
Payment for asset acquisition (net of cash and cash equivalents)	45.3	-	(35.25)
Redemption of investment in other funds		-	0.90
Interest received		94.48	82.07
Net cash (used in) investing activities (B)		(4,877.52)	(2,257.27)
Cash flows from financing activities S			
Proceeds from issue of equity shares	15 & 16	15.58	19.49
Acquisition of non-controlling interest	16.6 (ii)	-	(422.00)
Proceeds from long-term borrowings		2,220.84	2,900.17
Repayment of long-term borrowings		(775.61)	(1,511.40)
Repayment of principal portion of lease liability		(261.64)	(455.47)
Settlement of deferred consideration		(41.98)	-
Interest paid on lease liability		(819.95)	(506.29)
Interest and other borrowing cost paid		(761.62)	(664.66)
Net cash (used in) financing activities (C)		(424.38)	(640.16)
Net (decrease) in cash and cash equivalents (A+B+C)		(2,130.81)	(51.64)
Cash and cash equivalents at the beginning of the year	14	1,660.18	1,711.82
Cash and cash equivalents at the end of the year	14	(470.63)	1,660.18

For the purpose of statement of cash flows, cash and cash equivalent comprises the followings:

	As at 31 March 2025	As at 31 March 2024
(a) Cash on hand	22.95	10.76
(b) Cheques, drafts on hand	4.22	1.73
(c) Balance with bank		
In current accounts and EEFC accounts	1,265.42	576.90
In deposit accounts	1,066.12	2,136.74
Cash and cash equivalent as per balance sheet	2,358.71	2,726.13
Less: Bank overdrafts repayable on demand (refer note 18)	(2,829.34)	(1,065.95)
Cash and cash equivalents as per the consolidated statement of cash flows	(470.63)	1,660.18



HealthCare Global Enterprises Limited
Consolidated Cash Flow Statement for the year ended 31 March 2025

Rs in million

S Reconciliation between opening and closing balance sheet for liabilities arising from financing activities for the year ended 31 March 2025:

Particulars	Term loan and deferred payment obligation #	Lease liabilities	Other borrowing cost	Total
Debt as at 1 April 2024	5,661.62	6,016.03	-	11,677.65
Cash flows including interest and other borrowing cost	998.63	(1,081.57)	(318.23)	(401.17)
- Interest and other borrowing cost*	550.23	806.82	298.52	1,655.57
- Non cash transactions @	(17.51)	2,608.62	19.71	2,610.82
Debt as at 31 March 2025	7,192.97	8,349.90	-	15,542.87

includes current maturities of Term loan and deferred payment obligation grouped under current borrowings.

*Interest and other borrowing cost include interest on Short term borrowings, bank charges measured at amortised cost etc.

@ Non cash transactions include lease liabilities recognised for new leases, adjustment for termination of lease contract, unrealised gain / loss on foreign currency fluctuations etc.

S Reconciliation between opening and closing balance sheet for liabilities arising from financing activities for the year ended 31 March 2024:

Particulars	Term loan and deferred payment obligation #	Lease liabilities	Other borrowing cost	Total
Debt as at 1 April 2023	3,958.98	5,018.63	-	8,977.61
Cash flows including interest and other borrowing cost	959.23	(961.76)	(235.12)	(237.65)
- Interest and other borrowing cost*	418.15	544.41	130.05	1,092.61
- Non cash transactions @	(10.91)	1,414.75	105.07	1,508.91
- Loan from acquisition of shares in Nagpur Cancer Hospital & Research Institute Private Limited, including interest accrued Rs. 1.78 million	336.17	-	-	336.17
Debt as at 31 March 2024	5,661.62	6,016.03	-	11,677.65

includes current maturities of Term loan and deferred payment obligation grouped under current borrowings

*Interest and other borrowing cost include interest on Short term borrowings, bank charges measured at amortised cost etc

@ Non cash transactions include lease liabilities recognised for new leases, changes due to remeasurement of lease liabilities, unrealised gain / loss on foreign currency fluctuations etc

Material accounting policies

3

The accompanying notes are an integral part of these consolidated financial statements

As per our reports of even date attached

for BSR & Co. LLP

Chartered Accountants

Firm's registration number: 101248W W-100022


Vikash Gupta
Partner
Membership number: 064597

for and on behalf of the Board of Directors of
HealthCare Global Enterprises Limited


Dr. B.S. Ajaikumar
Executive Chairman
DIN: 00713779
Place: Bengaluru
Date: 24 May 2025


Meghraj Arvindrao Gore
Chief Executive Officer
Place: Bengaluru
Date: 24 May 2025


Anjali Ajaikumar Rossi
Director
DIN: 08057112
Place: Geneva
Date: 24 May 2025


Ruby Ritolia
Chief Financial Officer
Place: Bengaluru
Date: 24 May 2025


Syru Manuel
Company Secretary
Place: Bengaluru
Date: 24 May 2025

Place: Bengaluru
Date: 24 May 2025




Consolidated Statement of changes in equity for the year ended 31 March 2025

a. Equity share capital *

No. of shares	Rs. in Million
As at 01 April 2023	
Issue of equity shares pursuant to exercise of employee share options under the Employee Stock Option Scheme 2014 and Employee Stock Option Scheme 2021 (refer note 38(C))	139,116,062
	1,391.16
	174,625
	1.74
Balance as at 31 March 2024	139,289,687
	1,392.90
Issue of equity shares pursuant to exercise of employee share options under the Employee Stock Option Scheme 2014 and the Employee Stock Option Scheme 2021 (refer note 38(C))	125,683
	1.26
Balance as at 31 March 2025	139,415,370
	1,394.16

b. Other equity *

Particulars	Note No.	Reserves and Surplus					Items of other comprehensive income			Equity attributable to shareholders of the company	Non-controlling interests	Total other equity
		Capital reserve	Securities premium	Share options outstanding account	Retained earnings	Foreign currency translation reserve	Re-measurements of the defined benefit plans					
Balance as at 01 April 2023		6.77	11,648.85	120.28	(4,522.45)	(22.93)	(16.46)		7,214.06	88.94	7,303.00	
Profit / (loss) for the year		-	-	-	481.55	-	(6.42)	-	481.55	(68.21)	413.34	
Other comprehensive income / (loss) for the year (net of tax)		-	-	-	-	2.14	(6.42)	-	(4.28)	(0.35)	(4.63)	
Total comprehensive income / (loss)		-	-	-	481.55	2.14	(6.42)	-	477.27	(68.56)	408.71	
Transactions with owners of the Company												
<i>Contributions and distributions</i>												
Premium received on shares issued during the year	17.75	-	17.75	-	-	-	-	-	17.75	-	17.75	
Transferred to Securities premium account on exercise of ESOPs	16.2	-	22.13	(22.13)	-	-	-	-	-	-	-	
Transferred to retained earnings on lapse of vested ESOPs	16.2	-	(1.06)	1.06	-	-	-	-	-	-	-	
Expense on employee stock option scheme	16.2	-	-	78.46	-	-	-	-	78.46	-	78.46	
<i>Changes in ownership interests</i>												
Change in fair value of gross obligations over written put options issued to the non-controlling interests	16.6	-	-	-	(90.00)	-	-	-	(90.00)	-	(90.00)	
Change in ownership in subsidiaries without change in control	17	-	-	-	(832.64)	-	-	-	(832.64)	378.00	(459.64)	
Balance as at 31 March 2024		6.77	11,688.73	175.55	(4,962.48)	(20.79)	(22.88)	-	6,864.90	393.38	7,258.28	
Profit / (loss) for the year		-	-	-	444.10	-	-	-	444.10	44.24	488.34	
Other comprehensive income / (loss) for the year (net of tax)		-	-	-	-	14.94	1.20	-	16.14	1.87	18.01	
Total comprehensive income / (loss)		-	-	-	444.10	14.94	1.20	-	460.24	46.11	506.35	
Transactions with owners of the Company												
<i>Contributions and distributions</i>												
Premium received on shares issued during year	14.32	-	14.32	-	-	-	-	-	14.32	-	14.32	
Transferred to Securities premium account on exercise of ESOPs	16.2	-	16.79	(16.79)	-	-	-	-	-	-	-	
Expense on employee stock option scheme	16.2	-	-	64.79	-	-	-	-	64.79	-	64.79	
<i>Changes in ownership interests</i>												
Recognition of gross obligation towards put option	16.6	-	-	-	(608.00)	-	-	-	(608.00)	-	(608.00)	
Subsequent remeasurement for gross obligation towards put option	16.6	-	-	-	(26.00)	-	-	-	(26.00)	-	(26.00)	
Derogation of liability towards put option	16.6	-	-	-	1,060.00	-	-	-	1,060.00	-	1,060.00	
Acquisition of subsidiaries	45.1	-	-	-	-	-	-	-	-	236.56	236.56	
Balance as at 31 March 2025		6.77	11,719.84	223.55	(4,092.38)	(5.85)	(21.68)	-	7,830.25	676.05	8,506.30	



14

Securities premium

Securities premium is used to record the premium on issue of equity shares. The reserve is utilised in accordance with the provisions of the Companies Act, 2013

Share option outstanding Account

The Company has employee stock option plans for eligible employees of the Company and its group companies. Refer note 38 for further details on these plans. The amounts recorded in share options outstanding account are transferred to securities premium upon exercise of stock options and transferred to retained earnings on account of vested stock options not exercised by employees

Capital reserve

Capital reserve is created on account of business combinations. The reserve will be utilised in accordance with the provisions of the Companies Act, 2013

Retained earnings

Retained earnings represent the amount of accumulated earnings of the Company

Foreign currency translation reserve (FCTR)

The exchange differences arising from the translation of financial statements of foreign operations with functional currency other than Indian rupees is recognised in other comprehensive income and is presented within equity in the FCTR. Exchange difference accumulated in the foreign currency translation reserve are reclassified to Statement of Profit and Loss on the disposal of the foreign operation.

Remeasurement of defined benefit plan

This represents the actuarial gain and losses on defined benefit plan

* There are no changes in equity share capital and other equity due to prior period errors

Material accounting policies

The accompanying notes are an integral part of these consolidated financial statements 3

As per our reports of even date attached

for BSR & Co. LLP
Chartered Accountants

Firm's registration number 101248W-W-106022

Vikash Gupta
Partner

Membership number 064597

Place Bengaluru
Date 24 May 2025

for and on behalf of the Board of Directors of
HealthCare Global Enterprises Limited


B. S. R. Srikumar
Chairman and CEO
DIN: 00713779


Place Bengaluru
Date 24 May 2025


Kuby Ritolia
Chief Financial Officer

Place Bengaluru
Date 24 May 2025


Arvindrao Gore
Chief Executive Officer

Place Bengaluru
Date 24 May 2025


Manu Manuel
Company Secretary

Place Bengaluru
Date 24 May 2025


Arjati Ajitkumar Rossi
Director

DIN: 08057112
Place Geneva
Date 24 May 2025



HealthCare Global Enterprises Limited ('the Company') and its subsidiaries (collectively referred to as "the Group") and its joint venture is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector. The Company is a public company incorporated and domiciled in India and has its registered office at #8, P Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027

The consolidated financial statements for the year ended 31 March 2025 were approved by the Board of Directors and authorised for issue on 24 May 2025

2.1 Basis of preparation of the consolidated financial statements

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time

(b) Functional and presentation currency

These consolidated financial statements are presented in Indian Rupees (Rs), which is also the Group's functional currency. All amounts are in Indian Rupees million except share data and per share data, unless otherwise stated. The functional currency of foreign subsidiary is the currency of the primary economic environment in which the entity operates

(c) Basis of measurement

The consolidated financial statements have been prepared on the historical cost basis except for the following items

Items	Measurement basis
Non-derivative financial instruments at FVTPL	Fair Value
Contingent consideration assumed in business combination	Fair Value
Net defined benefit (asset)/ liability	Present value of defined benefit obligations less fair value of plan assets
Written put option	Fair value of gross obligations

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date

(d) Use of estimates and judgements

In preparing these consolidated financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

Application of accounting policies that require accounting estimates involving judgments and the use of assumptions in the consolidated financial statements have been disclosed below

Judgements

- Note 6 - Leasing arrangements: Evaluation whether an arrangement qualifies to be a lease based on the requirements of the relevant standard. Identification of a lease requires significant management judgment

- Note 5 - Property, plant and equipment: Timing of capitalisation and nature of cost capitalised

- Note 46 - The Management has assessed whether or not the Group has control over the entities consolidated

Assumptions and estimation uncertainties

- Note 6 - Leasing arrangements: Determination of lease term and discount rate

- Note 5 - Estimation of useful life of property, plant and equipment

- Note 19 - Gross obligations on written put option

- Note 23 - Revenue: estimation of disallowances

- Note 32 - Deferred tax balances (net): Timing and level of future taxable profit

- Note 33 - Recognition and measurement of provisions and contingencies: key assumptions about the likelihood and magnitude of an outflow of resources.

- Note 37 - Employee benefit plans: key actuarial assumptions.

- Note 7A - Goodwill impairment assessment: Key inputs considered i.e. discount rate, estimate of revenue growth rate, terminal growth rate and profitability

- Note 40 and 13 - Expected credit loss: Forward adjustment to the collected trend

- Note 20 - Deferred government grant: Timing of meeting export obligations

- Note 45 - Business combination: Identification of intangible asset, fair value of assets acquired and liabilities assumed and measurement of contingent consideration

(e) Current / Non-current classification

Based on the time involved between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Group has identified twelve months as its operating cycle for determining current and non-current classification of assets and liabilities in the balance sheet.

(f) Measurement of fair values

The Group accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. The Group has an established control framework with respect to the measurement of fair values. This includes an internal finance team that has overall responsibility for overseeing all significant fair value measurement, including level 3 fair values, and reports directly to the chief financial officer.

Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities

- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices)

- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs)

When measuring the fair value of an asset or a liability, the Group uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Group recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.



Vy.

2.2 Basis of consolidation

(a) Subsidiaries

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

Consolidation procedure followed is as under:

Items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries are combined like to like basis. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognized in the consolidated financial statements at the acquisition date.

(b) Non-controlling interests (NCI)

NCI are measured at their proportionate share of the acquiree's net identifiable assets at the date of acquisition. Changes in the Group's equity interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. The carrying amount of non-controlling interests is the amount of those interests at initial recognition plus the non-controlling interests' share of subsequent changes in equity. Total comprehensive income is attributed to non-controlling interests even if it results in the non-controlling interest having a deficit balance.

Gross obligation of written put option granted to NCI is recognised as a financial liability with a corresponding debit to retained earnings. Any subsequent change in the carrying amount of the put liability is recognised in other equity. In case the put option expires unexercised, then the put liability is reversed against other equity.

When the parent has the right to settle either in cash or its own equity instrument, the Company recognises NCI share as a component of equity and put option derivative liability separately.

(c) Loss of control

When the Group loses control over a subsidiary, it derecognises the assets and liabilities of the subsidiary, and any related NCI and other components of equity. Any interest retained in the former subsidiary is measured at fair value at the date the control is lost. Any resulting gain or loss is recognised in the statement of profit and loss.

(d) Equity accounted investees

The Group's interests in equity accounted investees comprise interest in a joint venture. A joint venture is an arrangement in which the Group has joint control and has rights to the net assets of the arrangement, rather than the rights to its assets and obligations for its liabilities.

Interests in joint venture are accounted for using the equity method. They are initially recognised at cost which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Group's share of profit or loss and other comprehensive income of equity-accounted investees until the date on which significant influence or joint control ceases.

(e) Transactions eliminated on consolidation

Intra-group balances and transactions, and any unrealised income and expenses arising from intragroup transactions, are eliminated. Unrealised gains arising from transactions with equity accounted investees are eliminated against the investment to the extent of the Group's interest in the investee. Unrealised losses are eliminated in the same way as unrealised gains, but only to the extent that there is no evidence of impairment.

3 Summary of material accounting policies

(a) Revenue recognition

Medical services

Revenue primarily comprises fees charged for inpatient and outpatient hospital services. Services include charges for accommodation, medical professional services, equipment, radiology, laboratory and pharmaceutical goods used in treatments given to patients. As per Ind AS 115, "Revenue from contracts with customers", revenue from hospital services are recognized as and when services are performed. The Group assesses the distinct performance obligation in the contract and measures revenue based on the consideration specified in a contract with the customer and excludes taxes and duties collected on behalf of the Government. Further, the revenue is only recognized to the extent that it is highly probable that a significant reversal will not occur (adjusted for discounts and disallowances). The Company based on contractual terms and past experience determines the performance obligation satisfaction over time. Unbilled revenue is recorded for the service rendered where the patients are not discharged and final invoice is not raised for the services.

Sale of medical and non-medical items

Pharmacy Sales are recognized when the control of the products being sold is transferred to the customer based on the consideration agreed with the customer and excludes taxes or duties collected on behalf of the Government.

Other operating revenue


Other operating revenue comprises revenue from various ancillary revenue generating activities like facilitation of training programmes, operations and maintenance arrangements as per the management agreement with other entities. The service income is recognized only once the services are rendered, there is no unfulfilled performance obligation as per the terms of agreement and no significant future uncertainties exist.

Disaggregation of revenue

The Group disaggregates revenue from hospital services (medical and healthcare services), sale of medical and non-medical items and other operating income. The Group believes that this disaggregation best depicts how the nature, amount, timing and uncertainty of Group's revenues and cash flows are affected by industry, market and other economic factors.

Interest income

For all financial assets measured at amortised cost, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of all financial liability. When calculating the effective interest rate, the Group estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example, prepayment, extension) but does not consider the expected credit losses.



V.S.

3 Summary of material accounting policies (Contd..)

(b) Leases

Group as a lessee

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Group assesses whether

- the contract involves the use of an identified asset,
- the Group has the right to obtain substantially all the economic benefits from use of the asset throughout the period of use, and
- the Group has the right to direct the use of the asset

At inception or on reassessment of a contract that contains a lease component, the Group allocates the consideration in the contract to each lease component on the basis of the relative stand-alone prices of the lease components and the aggregate stand-alone price of the non-lease components

The Group recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability, adjusted for any lease payments made at or before the commencement date, less any lease incentives received, plus any initial direct costs incurred and an estimate of the costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located

The right-of-use asset is subsequently measured at cost less accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the consolidated statement of profit and loss.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the incremental borrowing rate applicable to the entity within the Group. Generally, the Group uses its incremental borrowing rate as the discount rate. The lease payments shall include fixed payments, variable lease payments, residual value guarantees, exercise price of a purchase option where the Group is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease.

The lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments.

The Group recognises the amount of the re-measurement of lease liability as an adjustment to the right-of-use asset. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Group recognises any remaining amount of the re-measurement in consolidated statement of profit and loss.

The Group has elected not to recognise right-of-use assets and lease liabilities for short-term leases of all assets that have a lease term of 12 months or less and leases of low-value assets. The Group recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term. Variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date and the amounts expected to be payable under a residual value guarantee.

(c) Foreign currency transactions

Transactions in foreign currencies are translated into the respective functional currencies of Group at the exchange rates at the dates of the transactions or an average rate approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date.

Exchange differences on monetary items are recognised in the Statement of profit and loss in the period in which they arise.

Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction.

Income and expense items in foreign currency are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used.

(d) Foreign currency translations

For the purpose of presenting consolidated financial statements, the assets and liabilities of the Group's foreign operations that have a functional currency other than Indian rupees are translated into Indian rupees using exchange rates prevailing at the reporting date. Income and expense items are translated at the average exchange rates for the period. Exchange differences arising, if any, are recognised in other comprehensive income and held in foreign currency translation reserve (FCTR), a component of equity, except to the extent that the translation difference is allocated to non-controlling interest. When a foreign operation is disposed off, the relevant amount recognised in FCTR is transferred to the statement of consolidated profit and loss as part of the profit or loss on disposal.

(e) Borrowing costs

Borrowing costs include

- (i) interest expense calculated using the effective interest rate method,
- (ii) finance charges in respect of lease liability, and
- (iii) exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs.


Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.

All other borrowing costs are recognised in the statement of profit and loss in the period in which they are incurred.

(f) Employee benefits

Short-term employee benefits

Short-term employee benefits are measured on an undiscounted basis and expensed as the related service is provided. A liability is recognised for the amount expected to be paid under short-term cash bonus, if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.



Vy.

Employee benefits (contd.)

Defined benefit plan

For defined benefit plans, the cost of providing benefits is determined using the projected unit credit method, with actuarial valuations being carried out at the end of each annual reporting period. When the calculation results in a potential asset for the Group, the recognised asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reduction in future contributions to the plan (the asset ceiling). To calculate the present value of economic benefits, consideration is given to any applicable minimum funding requirements.

Remeasurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding net interest), is reflected in the balance sheet with a charge or credit recognised in other comprehensive income in the period in which they occur. The service cost (including current service cost, past service cost, as well as gains and losses on curtailments and settlements) is recognised in the Statement of profit and loss in the line item 'Employee benefits expense'. The net interest expense (income) on the net defined benefit liability (asset) for the period is determined by applying the discount rate determined by reference to market yields at the end of the reporting period on government bonds. The net interest expense is recognised in the line item 'Finance costs'.

Defined contribution plan

A defined contribution plan is post-employment benefit plan under which an entity pays specified contributions to separate entity and has no obligation to pay any further amounts. The Group makes specified obligations towards employee provident fund and employee state insurance to Government administered provident fund scheme and ESI scheme which is a defined contribution plan. Payments to defined contribution plans are recognised as an expense when employees have rendered service entitling them to the contributions. The Group's contributions are recognized as an expense in the statement of profit and loss during the period in which the employee renders the related service.

Compensated absences

The employees can carry-forward a portion of the unutilized accrued compensated absences and utilize it in future service periods or receive cash compensation on termination of employment. Since the employee has unconditional right to avail the leave, the benefit is classified as a short term employee benefit. The Group records an obligation for such compensated absences in the period in which the employee renders the services that increase this entitlement. The obligation is measured on the basis of independent actuarial valuation using the projected unit credit method. Remeasurements are recognised in profit or loss in the period in which they arise.

Share-based payment transactions

The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model and Group's estimate of equity instruments that will vest. That cost is recognised, together with a corresponding increase in share-options outstanding account in equity, over the period in which the performance and/or service conditions are fulfilled in employee benefits expense.

(g) Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax. It is recognised in profit or loss except to the extent that it relates to a business combination, or items recognised directly in equity or in Other comprehensive income.

(i) Current tax

Current tax comprises the expected tax payable on the taxable profit for the year and any adjustment to the tax payable or receivable in respect of previous years. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group's current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realize the assets and settle the liability on a net basis or simultaneously.

(ii) Deferred tax


Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition of assets and liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss at the time of transaction. Deferred tax liability is also not recognised on taxable temporary differences arising on the initial recognition of goodwill.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously. Temporary differences in relation to a right-of-use asset and a lease liability for a specific lease are regarded as a net package (the lease) for the purpose of recognising deferred tax.



3 Summary of material accounting policies (Contd.,)

(h) Property, plant and equipment

The cost of an item of property, plant and equipment shall be recognised as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably

Property, plant and equipment (including capital work-in progress) are measured at cost which includes capitalized borrowing costs, less accumulated depreciation and impairment losses, if any. The cost of an item of Property, plant and equipment comprises its purchase price, including import duties and other non-refundable taxes or levies, freight, any directly attributable cost of bringing the asset to its working condition for its intended use and estimated cost of dismantling and restoring onsite; any trade discounts and rebates are deducted in arriving at the purchase price. Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Group and the cost of the item can be measured reliably. Cost includes expenditures directly attributable to the acquisition of the asset.

Transition to Ind AS:

The cost of property, plant and equipment as at 1 April 2015, the Group's date of transition to Ind AS, was determined with reference to its carrying value recognised as per the previous GAAP (deemed cost), as at the date of transition to Ind AS.

The Group depreciates property, plant and equipment over the estimated useful life on a straight-line basis from the date the assets are ready for intended use. The estimated useful lives of assets for the current and comparative period of significant items of property, plant and equipment are as follows:

Asset category	Useful life as per the management	As per schedule II of Companies Act, 2013
Buildings	60 years	60 years
Plant and Medical Equipment (other than Solar power plant)	10, 13 or 15 years	10, 13 or 15 years
Solar power plant	25 years	Not specified
Data processing equipment	3 years	3 years
Electrical installations	10 years	10 years
Furniture and fixtures	10 years	10 years
Office equipment	5 years	5 years
Vehicles	8 years	8 years

Useful lives are reviewed at each reporting date and adjusted if appropriate. Based on technical evaluation and consequent advice, the management believes that its estimates of useful lives as given above best represent the period over which management expects to use these assets.

The cost and related accumulated depreciation are eliminated from the consolidated financial statements upon sale or disposition of the asset and the resultant gains or losses are recognized in the consolidated statement of profit and loss. Amounts paid towards the acquisition of property, plant and equipment outstanding as of each reporting date are recognized as capital advance and the cost of property, plant and equipment not ready for intended use before such date are disclosed under capital work-in-progress.

Assets acquired under leasehold improvements are amortized over the lower of estimated useful life and lease term.

Freehold land is carried at historical cost less any accumulated impairment losses.

(i) Intangible assets

Intangible assets acquired on business combination are recognised at fair value as at the date of acquisition. Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortisation and accumulated impairment losses. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in the statement of profit and loss as incurred. Amortisation is recognised on a straight-line basis over their estimated useful lives. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses.

Useful lives of intangible assets

Estimated useful lives of the intangible assets are as follows:

Asset category	Useful Life
Computer software	3 years
Software for plant and machinery	13 years
Trade name	3 years
Brand	18 years
Non compete agreements	3 years
Referral network	25 years
Intellectual Property for contract research	10 years

The estimated useful life of intangible assets acquired by the Group has been determined based on number of factors including the competitive environment, operating plan and macro-economies of the country in which the brand operates.

(j) Goodwill

Goodwill arising on a business combination is initially measured at excess of purchase consideration over fair value of identified net asset taken over. Subsequent measurement is at initial recognition less any accumulated impairment losses. Goodwill is tested annually for impairment. An impairment loss in respect of goodwill is not reversed subsequently.

(k) Government grants

Government grants are recognised where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. Where the Group receives non-monetary grants, the asset and the grant are accounted at fair value and recognised in the consolidated statement of profit and loss over the expected useful life of the assets. If based on the estimate it is expected that conditions attached with government grant may not be fulfilled, then a financial liability is recognised for repayment along with interest, where applicable. The financial liability is created by first reversing the balance available in the deferred government grant and the balance as a charge to the consolidated statement of profit and loss.

VH



3 Summary of material accounting policies (Contd.,)

(l) Inventories

Inventories are measured at the lower of cost and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. Cost of inventories comprises of all costs of purchase and other costs incurred in bringing the inventories to their present location, after adjusting for GST wherever applicable applying weighted average method.

Imported inventories are accounted for at the applicable exchange rates prevailing on the date of transaction.

(m) Provisions (other than employee benefits)

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that the Group will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

Onerous contracts

A contract is considered to be onerous when the expected economic benefits to be derived by the Group from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Group recognises any impairment loss on the assets associated with that contract.

(n) Financial instruments

a. Recognition and initial measurement

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Group becomes a party to the contractual provisions of the instrument.

A financial asset (except trade receivable) or financial liability is initially measured at fair value plus / minus, for an item not at fair value through profit and loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue. A trade receivable is initially measured at the transaction price.

b. Classification and subsequent measurement

Financial assets

On initial recognition, a financial asset is classified as measured at

- amortised cost,
- FVTPL.

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Group changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL.

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows, and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All financial assets not classified as measured at amortised cost as described above are measured at FVTPL. On initial recognition, the Group may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets: Business model assessment

The Group makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes the stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets,

- how the performance of the portfolio is evaluated and reported to the Group's management,
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed,
- how managers of the business are compensated – e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected, and
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Group's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest


For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Group considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Group considers

- contingent events that would change the amount or timing of cash flows,
- terms that may adjust the contractual coupon rate, including variable interest rate features,
- prepayment and extension features, and
- terms that limit the Group's claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.

VY.



Financial Instruments (Contd.)

Financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPL	These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in the statement of profit and loss.
Financial assets at amortised cost	These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in the statement of profit and loss. Any gain or loss on derecognition is recognised in the statement of profit and loss.

Financial liabilities: Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in the statement of profit and loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in the statement of profit and loss. Any gain or loss on derecognition is also recognised in the statement of profit and loss.

c. Derecognition

Financial assets

The Group derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Group neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Group enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

Financial liabilities

The Group derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire.

The Group also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in the statement of profit and loss.

d. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

(b) Impairment

(i) Financial assets (other than at fair value)

The Group assesses at each date of balance sheet, whether a financial asset or a group of financial assets is impaired. Ind AS 109 - Financial Instruments requires expected credit losses to be measured through a loss allowance. The Group recognises lifetime expected losses for all contract assets and / or all trade receivables that do not constitute a financing transaction. For all other financial assets, expected credit losses are measured at an amount equal to the twelve-month expected credit losses or at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly, since initial recognition.

Allowance for credit losses on receivables

The Group determines the allowance for credit losses based on historical loss experience adjusted to reflect current and estimated future economic conditions. The Group considered current and anticipated future economic conditions relating to industries the Group deals with and the countries where it operates.

(ii) Non-financial assets

Tangible and Intangible assets

Property, plant and equipment, capital work-in-progress and intangible assets with finite life are evaluated for recoverability whenever there is an indication that their carrying amounts may not be recoverable. If any such indication exists, the recoverable amount (i.e. higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for cash generating unit (CGU) to which the asset belongs.

If the recoverable amount of an asset (or CGU) is estimated to be less than its carrying amount, the carrying amount of the asset (or CGU) is reduced to its recoverable amount. An impairment loss is recognised in the statement of profit and loss. In respect of assets other than Goodwill for which impairment loss has been recognised in prior periods, the Group reviews at each reporting date whether there is any indication that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

(p) Earnings / loss per share (EPS)

Basic earnings / loss per share are computed by dividing profit attributable to equity shareholders of the Group by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed using the weighted-average number of equity and dilutive equivalent shares outstanding during the period, using the treasury stock method for options and warrants, except where the results would be anti-dilutive.

(q) Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Group or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Group does not recognize a contingent liability but discloses its existence in the consolidated financial statements unless the possibility of an outflow of resources embodying economic benefits is remote.

Contingent liabilities and commitments are reviewed by the management at each balance sheet date.

(r) Cash flow statement

Cash flows are reported using the indirect method, whereby net profit / loss before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Group are segregated. Bank overdrafts and investment in liquid mutual funds are classified as cash and cash equivalents for the purpose of cash flow statement, as they form an integral part of an entity's cash management.

Vy.



3 Summary of material accounting policies (Contd.,)

(s) Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less

For the purpose of cash flow statement, cash and cash equivalent includes cash in hand, in banks, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less, net of outstanding bank overdrafts that are repayable on demand and are considered part of the cash management system

(t) Segment reporting

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses and for which discrete financial information is available. Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The Chairman of the Group is responsible for allocating resources and assessing performance of the operating segments and accordingly is identified as the Chief Operating Decision Maker (CODM). The CODM evaluates the Group's performance and allocates resources on overall basis.

(u) Business combinations

In accordance with Ind AS 103, "Business combinations" the Group accounts for acquisitions of businesses using the acquisition method. The consideration transferred for the business combination is measured at fair value as at the date the net identifiable assets are acquired. Purchase consideration paid in excess of fair value of net identifiable assets acquired is recognised as goodwill. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognised in OCI and accumulated in equity as capital reserve if there exists clear evidence of the underlying reasons for classifying the business combination as resulting in a bargain purchase, otherwise the gain is recognised directly in equity as capital reserve. Transaction costs are expensed as incurred, except to the extent related to the issue of debt or equity securities.

The consideration transferred does not include amounts related to the settlement of pre-existing relationships with the acquiree.

Any contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that meets the definition of financial instrument is classified as equity, then its not remeasured subsequently and settlement is accounted for within equity. Other contingent consideration is remeasured at fair value at each reporting date and changes in the fair value of the contingent consideration are recognised in the statement of profit and loss.


(v) Exceptional items

Exceptional items refer to items of income or expense within the consolidated statement of profit and loss from ordinary activities which are non-recurring and are of such size, nature or incidence that their separate disclosure is considered necessary to explain the performance of the Group.

4 Recent pronouncements

Ministry of Corporate Affairs ("MCA") notifies new standard or amendments to the existing standards under companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended March 31, 2025, MCA has notified IND AS -117 Insurance Contracts and amendments to Ind AS 116 - Leases, relating to sale and leaseback transactions, applicable to the Group w.e.f April 1, 2024. The Group has reviewed the new pronouncements and based on its evaluation has determined that it does not have any significant impact in its financial statements.

On May 9, 2025, MCA notifies the amendments to Ind AS 21 - Effects of Changes in Foreign Exchange Rates. These amendments aim to provide clearer guidance on assessing currency exchangeability and estimating exchange rates when currencies are not readily exchangeable. The amendments are effective for annual periods beginning on or after April 1, 2025. The Group does not expect this amendment to have any significant impact in its consolidated financial statements.



Vy.

HealthCare Global Enterprises Limited
Notes to the consolidated financial statements for the year ended 31 March 2025 (continued)

(Rs in million)


5 Property, plant and equipment and capital work-in-progress

Description of Assets	Freehold land	Buildings	Leasehold Improvements	Plant and medical equipment	Office Equipment	Furniture and Fixtures	Data processing equipments	Electrical installation	Vehicles	Total (A)	Capital work in progress (refer note 5.2)
I. Gross block											
Balance as at 01 April 2023	647.23	1,482.34	2,194.56	10,224.46	104.96	403.79	256.33	277.27	42.20	15,633.15	181.78
Additions (refer note 5.1)	-	37.99	218.34	520.11	25.87	29.91	118.37	37.14	-6.15	993.88	1,002.11
Disposals	-	-	(88.64)	(74.23)	(5.80)	(11.33)	(8.83)	(7.39)	-	(106.22)	-
Capitalised during the year	-	-	-	-	-	-	-	-	-	-	(352.05)
Acquired through business combinations (refer note 45.2)	-	-	-	47.15	1.24	1.69	0.38	0.25	-	50.71	-
Acquired through asset acquisition (refer note 45.3)	-	490.80	-	17.28	-	0.42	-	-	-	508.50	-
Exchange fluctuation	-	1.53	0.13	2.76	(0.00)	(0.00)	(0.01)	-	0.01	4.41	-
Balance as on 31 March 2024	647.23	2,012.66	2,324.39	10,737.54	126.27	424.48	366.23	307.27	48.35	16,994.43	831.84
Additions (refer note 5.1)	-	38.58	1,023.51	1,491.04	30.82	76.97	63.50	180.99	8.07	2,913.48	1,111.23
Disposals	-	-	(105.31)	(341.40)	(6.40)	(28.10)	(0.13)	-	(0.42)	(481.76)	-
Capitalised during the year	-	-	-	-	-	-	-	-	-	-	(1,695.51)
Acquired through business combinations (refer note 45.1)	385.04	0.50	177.06	309.24	2.00	8.87	16.44	-	23.05	921.20	-
Exchange fluctuation	-	4.73	0.42	8.48	0.15	0.23	0.41	-	0.10	14.52	-
Balance as at 31 March 2025	1,032.27	2,056.47	3,420.07	12,204.90	152.84	482.45	446.45	488.26	78.15	20,361.87	247.56
II. Accumulated depreciation and impairment											
Balance as at 01 April 2023	-	141.18	883.99	4,220.50	101.98	231.49	184.85	125.31	25.60	5,914.90	-
Depreciation expense	-	37.56	159.62	754.77	11.08	44.22	45.63	34.62	4.60	1,092.11	-
Eliminated on disposal of assets	-	-	(85.81)	(45.38)	(4.09)	(10.24)	(8.56)	(7.39)	-	(161.47)	-
Exchange fluctuation	-	0.23	0.08	1.39	0.03	0.05	0.18	-	-	1.95	-
Balance as on 31 March 2024	-	178.97	957.88	4,931.28	109.01	265.53	222.10	152.54	30.20	6,847.49	-
Depreciation expense	-	41.57	199.89	854.50	15.86	49.48	64.98	41.53	10.25	1,278.06	-
Eliminated on disposal of assets	-	-	(118.89)	(304.67)	(6.19)	(23.80)	(0.20)	(0.37)	(0.42)	(454.54)	-
Exchange fluctuation	-	0.25	0.09	1.08	0.03	0.06	0.15	-	0.02	1.68	-
Balance as at 31 March 2025	-	220.79	1,038.97	5,482.19	118.71	291.27	287.03	193.70	40.05	7,672.69	-
Net block as at 31 March 2024	647.23	1,833.69	1,366.51	5,806.26	17.26	158.95	144.13	154.73	18.15	10,146.94	831.84
Net block as at 31 March 2025	1,032.27	1,835.68	2,381.10	6,722.71	34.13	191.18	159.42	294.56	38.10	12,689.18	247.56

Refer note 18 for details of charge created on property, plant and equipment

5.1 Additions during the year include:

- Directly attributable expenses capitalised of Rs 190.65 million (31 March 2024: Rs. 11.19 million). Total borrowing cost capitalised (included in directly attributable expenses) is Rs. 109.96 million (31 March 2024: Rs. 5.25 million) relating to Lease Liability using a capitalisation rate of 10%.
- Government grant recognised at fair value as per Ind AS 20, accounting for government grants and disclosure of government assistance (refer note 20).
- Acquisition of plant and ~~medical~~ equipment through deferred payment settlement scheme is Rs 94.84 million (31 March 2024: Rs. 24.48 million).



VY

5.2 Capital work-in-progress (CWIP) ageing schedule

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Projects in progress					
As at 31 March 2025	208.93	36.62	1.77	0.24	247.56
As at 31 March 2024	744.89	75.02	6.18	5.75	831.84
Projects temporarily suspended					
As at 31 March 2025	-	-	-	-	-
As at 31 March 2024 (refer note (i) below)	-	-	-	-	-
Total Capital work-in-progress					
As at 31 March 2025	208.93	36.62	1.77	0.24	247.56
As at 31 March 2024	744.89	75.02	6.18	5.75	831.84

(i) Project abandoned / temporarily suspended:

In the earlier years, the Company had recognised impairment aggregating to Rs. 835.46 million (including capital work-in progress, capital advances, right of use asset, security deposit and other committed costs) towards a greenfield project at leased premises in Gurnigram which was temporarily suspended in the year ended 31 March 2022. During the previous year ended 31 March 2024, the underlying lease agreement had been terminated and the project was written-off pursuant to the resolution passed by the Board of the Directors of the Company. Further, the management had concluded that the other committed project cost of Rs. 39.05 million which was accrued earlier is no longer payable and had been written back in the Statement of profit and loss as exceptional items.

(ii) There were no projects that exceeded its cost compared to its original budget as at 31 March 2025 and 31 March 2024 except in respect of hospital construction project in Ahmedabad where there was an increase in the project cost from its original budget of Rs. 825 million to Rs. 1,075 million during the year ended 31 March 2024 pursuant to the approval of Board of Directors of HCG Medi-Surge Hospitals Private Limited dated 20 December 2023. Further, pursuant to the approval of Board of Directors of the Company dated 20 May 2025, there is further increase in cost of aforesaid project as compared to the previously approved budget of Rs.1,075 million to Rs.1,218.55 million. As at 31 March 2025, the cost incurred for the aforesaid project amounting to Rs 1,054.74 million has been capitalised to the Property, Plant and equipment.

(iii) For capital work in progress, whose completion is over due as compared to its original plan.

Particulars	To be completed in				Total
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
As at 31 March 2025	154.85	-	-	-	154.85
As at 31 March 2024	-	-	-	-	-



V7.

6 Right of use assets and lease liabilities

Right-of-use-assets				
Description of assets	Leasehold rights of land (refer note (i) below)	Buildings	Plant and medical equipment	Total
I. Gross block				
Balance as at 01 April 2023	-	5,465.59	437.78	5,903.37
Additions	169.17	511.91	37.84	718.92
Acquisition through business combination (refer note 45.2)	-	251.17	-	251.17
Remeasurement of lease liabilities (refer note (ii) below)	-	746.57	-	746.57
Termination of lease (refer note (iii) below)	-	(43.60)	-	(43.60)
Disposal	-	(17.25)	-	(17.25)
Foreign currency translation	-	1.20	-	1.20
As at 31 March 2024	169.17	6,915.59	475.62	7,560.38
Additions	-	2,319.48	519.08	2,838.56
Acquisition through business combination (refer note 45.1)	-	9.73	-	9.73
Termination of lease (refer note (iii) below)	-	(254.81)	-	(254.81)
Foreign currency translation	-	4.98	-	4.98
As at 31 March 2025	169.17	8,994.97	994.70	10,158.84

II. Accumulated depreciation and impairment

Balance as at 01 April 2023	-	1,974.80	115.86	2,090.66
Depreciation expense	1.23	522.88	56.03	580.14
Eliminated on disposal of assets	-	(17.25)	-	(17.25)
Foreign currency translation	-	0.22	-	0.22
As at 31 March 2024	1.23	2,480.65	171.89	2,653.77
Depreciation expense	2.12	694.40	90.91	787.43
Eliminated on disposal of assets	-	(221.34)	-	(221.34)
Foreign currency translation	-	(2.14)	-	(2.14)
As at 31 March 2025	3.35	2,951.57	262.80	3,217.72
Net block as at 31 March 2024	167.94	4,434.94	303.73	4,906.61
Net block as at 31 March 2025	165.82	6,043.40	731.90	6,941.12

The Group has lease arrangements for leasehold rights of land, hospital buildings and medical equipments

The aggregate depreciation expense on the Right of use assets for the year amounting to Rs. 706.74 million (31 March 2024: 574.20 million) is included in the "Depreciation and Amortisation expense" in the Consolidated statement of Profit and Loss and Rs. 80.69 million (31 March 2024: Rs. 5.94 million) is capitalised.

Notes

(i) The Group has a hospital in Nagpur which is constructed on the Leasehold land allotted by Nagpur Investment Trust (NIT). The original allotment of the Land to NCHRI by NIT had been challenged by Legal Heirs of the seller, which was acquired by NIT through the Land acquisition Scheme. The Challenge was upheld by the Collector of Nagpur without giving proper chance of being heard by the stakeholders. NIT had filed a writ petition with the Hon'ble High court of Bombay, Nagpur Bench, challenging the order of the Collector and has obtained a Stay. The Holding Company also filed a Civil Application for Intervention and to add the Company as an Intervening party to the matter. The matter was subjudiced in the previous year and given the fact the holding Company is a Bonafide purchaser of rights in the Land by paying fair consideration, the Group believed that the above will not have any adverse impact on its rights to the lease-hold land.

During the year, the claimants filed representation letters with Hon'ble High court of Bombay, Nagpur Bench stating that they have no claims, including future claims on the hospital land and building. These representation shall ensure protection against any claims thereof. After taking into account such representation, the petition was allowed to be withdrawn by the Hon'ble High court of Bombay, Nagpur Bench via order dated 28 August 2024.

(ii) Pursuant to change in lease term and lease rentals for certain lease premises, the Group remeasured its lease liability with a corresponding adjustment to the Right-of-use assets.

(iii) The Group recognised gain for the year amounting to Rs. 10.24 million (31 March 2024: Rs. 17.57 million) on termination of lease contract.

The following is the break-up of current and non-current lease liabilities as at 31 March 2025 and 31 March 2024:

Particulars	As at 31 March 2025	As at 31 March 2024
Current lease liabilities	599.04	427.87
Non-current liabilities	7,750.86	5,588.16
Total	8,349.90	6,016.03



6 Right of use assets and lease liabilities (Contd..)

The table below provides details regarding the contractual maturities of Lease liabilities:

Particulars	Less than 1 year	1-2 years	2-3 years	3-4 years	More than 4 years	Total
As at 31 March 2025	1,341.86	1,205.97	1,162.75	1,121.48	9,477.86	14,309.92
As at 31 March 2024	951.27	842.31	851.73	804.61	6,520.01	9,969.93

Amounts recognised in consolidated statement of profit and loss

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Depreciation of right-of-use assets *	787.43	580.14
Interest on lease liabilities*	806.82	540.96
Rent expenses # (refer note 30)	269.37	218.40
Gain on termination of leases (refer note 25)	10.24	17.57

* Interest and depreciation expenses capitalised amounts to Rs. 109.96 million (31 March 2024: Rs. 5.25 million) and Rs. 80.69 million (31 March 2024: Rs. 5.94 million) respectively.

The Group has incurred expenses amounting to Rs. 106.24 million (31 March 2024: Rs. 62.80 million) towards short-term leases and Rs. 163.13 million (31 March 2024: Rs. 155.60 million) expenses towards variable rent.

Amounts recognised in Cash flow statement

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Repayment of principal portion of lease liability	261.64	455.47
Interest paid on lease liability	819.95	506.29
Payment towards short-term leases and variable rent	269.37	218.40
Total cash outflow for leases	1,350.96	1,180.16

Commitments for leases not yet commenced: The Group has committed to lease hospital building for its upcoming projects. The potential future lease payments (on undiscounted basis) for such leases: Rs. 239.85 million over a lease period in the range of 9 years (as at 31 March 2024: Rs. 2,920.58 million over the period of 18 to 30 years).



HealthCare Global Enterprises Limited
Notes to the consolidated financial statements for the year ended 31 March 2025 (continued)


(Rs in million)

Description of assets	Goodwill (refer note 7A below)	Other intangible assets							Total
		Computer software	Trade name and brand	Non Compete Agreements	Referral network	Intellectual Property for contract research	Tenacy rights	Software for plant and machinery	
I. Cost									
Balance as at 01 April 2023	1,942.34	512.60	128.83	-	23.20	35.20	11.00	3.42	714.25
Additions*	416.89	175.15	-	-	-	-	-	-	175.15
Disposals	-	(10.68)	-	-	-	-	-	-	(10.68)
Acquired through business combinations (refer note 45.2)	-	0.21	-	13.00	-	-	-	-	13.21
Foreign currency translation	0.13	-	1.43	-	-	-	-	-	1.43
Balance as at 31 March 2024	2,359.36	677.28	130.26	13.00	23.20	35.20	11.00	3.42	893.36
Additions*	-	24.28	-	-	-	-	-	-	24.28
Acquired through business combinations (refer note 45.1)	2,070.14	-	277.00	13.00	-	-	-	-	290.00
Foreign currency translation	-	-	4.43	-	-	-	-	-	4.43
Balance as at 31 March 2025	4,429.50	701.56	411.69	26.00	23.20	35.20	11.00	3.42	1,212.07
II. Accumulated amortisation and impairment losses									
Balance as at 01 April 2023	130.00	479.16	26.98	1.46	5.23	11.00	3.42	527.52	
Amortisation expense for the year	-	52.92	17.90	0.93	3.33	-	-	-	77.25
Disposals	-	(10.68)	-	-	-	-	-	-	(10.68)
Foreign currency translation	-	-	0.56	-	-	-	-	-	0.56
Balance as at 31 March 2024	130.00	521.40	45.44	2.39	8.56	11.00	3.42	594.65	
Amortisation expense for the year	-	56.86	60.85	0.93	3.49	-	-	-	128.64
Foreign currency translation	-	(0.29)	-	-	-	-	-	-	(0.29)
Balance as at 31 March 2025	130.00	577.97	106.29	3.32	12.05	11.00	3.42	723.00	
Net block as at 31 March 2024	2,229.35	155.88	84.82	10.83	20.81	26.64	-	-	298.71
Net block as at 31 March 2025	4,299.50	123.59	305.40	17.32	19.88	23.15	-	-	489.07

Refer note 18 for details of charge created on intangible asset.

* Includes intangible assets acquired through deferred payment settlement scheme amounting Rs.Nil million (31 March 2024- Rs. 86.48 million)

VY.



7A Goodwill

The carrying amount of goodwill has been allocated to the Cash Generating Units (CGU) as given below:

Particulars	As at	
	31 March 2025	31 March 2024
BACC Healthcare Private Limited	424.30	424.30
HCG Medi-Surge Hospitals Private Limited	53.46	53.46
Niruja Product Development and Healthcare Research Private Limited	0.25	0.25
Malnad Hospital and Institute of Oncology Private Limited	0.87	0.87
City Cancer Center, Vijaywada (CCC)	484.52	484.52
Diagnostic business	563.88	563.88
Suchirayu Health Care Solutions Limited	277.54	277.54
Cancer Care Center, Kenya	7.65	7.64
Cancer Center, Indore (refer note 45.2)	416.89	416.89
Vizag Hospital And Cancer Research Centre Private Limited (refer note 45.1)	2,070.14	-
Total	4,299.50	2,229.35

The recoverable amount of the underlying CGUs is based on its value in use, estimated on present value of the projected future cash flows. Following key assumptions were considered in performing impairment assessment:

Assumptions	As at 31 March 2025		As at 31 March 2024	
	Annual revenue growth rate	Terminal growth rate	Annual revenue growth rate	Terminal growth rate
BACC Healthcare Private Limited #	8% to 40%	5%	5% to 19%	5%
HCG Medi-Surge Hospitals Private Limited	9% to 13%	5%	8% to 17%	5%
City Cancer Center, Vijaywada (CCC)	12% to 16%	5%	8% to 13%	5%
Diagnostic business	10% to 12%	4%	10% to 17%	5%
Suchirayu Health Care Solutions Limited	8% to 27%	5%	8% to 19%	5%
Cancer Care Center, Kenya #	8% to 39%	5%	12% to 38%	4.66%
Cancer Center, Indore	16% to 71%	5%	10% to 15%	5%
Vizag Hospital And Cancer Research Centre Private Limited	6% to 36%	6%	17.79%	-

The values assigned to the key assumptions represent management's assessment of future trends and based on historical data from both external and internal sources. Discount rate reflects the current market assessment of the risks specific to a Cash Generating Unit (CGU) or group of CGUs. The discount rate is estimated based on the capital asset pricing method for respective CGU. The cash flow projections included specific estimates developed using internal forecasts. The planning horizon reflects the assumptions for short-to-midterm market developments. The Group believes that any reasonably possible change in the key assumptions on which a recoverable amount is based would not cause the aggregate carrying amount to materially exceed the aggregate recoverable amount of the cash generating unit.

In determining the value in use of CGUs - BACC Healthcare Private Limited and Cancer Care Center, Kenya, as at 31 March 2024, the management had used projected cash flows for a period of more than five years as the growth in revenues was not expected to reach a stable stage of operations in the next five years.



VG.

HealthCare Global Enterprises Limited
Notes to the consolidated financial statements for the year ended 31 March 2025 (continued)

(Rs in million)

8(A) Investment in equity accounted investees	As at 31 March 2025	As at 31 March 2024
Unquoted equity instruments		
In Joint Venture		
Advanced Molecular Imaging Limited 5,000 ordinary shares (as at 31 March 2024: 5,000 ordinary shares) of 100 Kenyan Shillings (KSH) each, fully paid up	43.09	33.60
Total	43.09	33.60

8(B) Investments	As at 31 March 2025	As at 31 March 2024
A) Non-current		
Investments carried at fair value through profit and loss (FVTPL)		
(i) In other companies - unquoted equity instruments		
Zoctr Health Private Limited [452 equity shares of Rs. 10 - each, fully paid up, (31 March 2024: 452 equity shares of Rs. 10 - each)]	-	-
International Stemcell Services Limited [10,860 equity shares of Rs. 100.- each, fully paid up, (31 March 2024: 10,860 equity shares of Rs. 100 - each, fully paid up)]	5.61	5.61
Epigeneres Biotech Private Limited [79 equity shares of Rs. 10.- each, fully paid up, (31 March 2024: 79 equity shares of Rs. 10 - each, fully paid up)]	-	-
Niramai Health Analytix Private Limited [10 equity shares of Re. 1- fully paid up, (31 March 2024: 10 equity shares of Re. 1 - fully paid up)]	0.07	0.07
(ii) In other companies - unquoted Preference shares		
Niramai Health Analytix Private Limited [4,881 series A preference shares of Rs. 10.- each, fully paid up, (31 March 2024: 4,881 series A preference shares of Rs. 10 - each, fully paid up)]	35.79	35.79
(iii) Mutual funds (Quoted)		
Religare Invesco Short Term Fund- 3,922 units @ Rs 3,941.87 (31 March 2024: 3,922 units @ Rs. 3,540.71)	15.46	13.89
SBI Mutual Fund- 24,272.75 units @ Rs 207.64 (31 March 2024: 24,272.75 units @ Rs 207.06)	5.04	5.04
(iv) Other funds (unquoted)		
Anthill Early Stage Fund - I 95.64 units of Class A units @ Rs 82,739 per unit (31 March 2024: 98.4 units at 92,480 per unit)	7.91	9.10
Investment in government or trust securities	0.15	0.15
Total Non current investments	70.03	69.65
Aggregate amount of quoted investments	20.50	18.93
Aggregate amount of market value of investments	20.50	18.93
Aggregate amount of unquoted investments	49.53	50.72

9 Loans (Unsecured)

	As at 31 March 2025	As at 31 March 2024
Considered good		
a) Advances to employees	26.96	19.43
Considered doubtful		
Total	26.96	19.43

10 Other financial assets


	As at 31 March 2025		As at 31 March 2024	
	Non Current	Current*	Non Current	Current*
Receivable from related parties (Refer note 43)	-	7.71	-	6.99
Security deposits (refer note 43)	496.80	42.09	399.57	60.81
Term deposits (original maturity more than 12 months) (refer note (i) below)	207.89	0.04	86.58	-
Considered doubtful				
Security deposits †	15.59	-	15.59	-
Less : Provision for impairment †	(15.59)	-	(15.59)	-
Other receivables	-	8.80	-	8.80
Less : Allowance for bad and doubtful receivables	-	(8.80)	-	(8.80)
Total	704.69	49.84	486.15	67.80

Note

(i) Term deposits include margin money deposits with banks and deposits given as security for obtaining bank guarantees

* Refer note 18 for details of charge created on other current financial assets.

† Rs.Nil million (31 March 2024 Rs.5.05 million) written-off during the year [refer note 5.2(i)]



HealthCare Global Enterprises Limited

Notes to the consolidated financial statements for the year ended 31 March 2025 (continued)

(Rs in million)

11 Other assets	As at 31 March 2025		As at 31 March 2024	
	Non Current	Current*	Non Current	Current*
Unsecured, considered good				
Capital advances	303.95	-	307.77	-
Advance for acquisition of business (refer note 11.1 below)	-	-	20.00	-
Prepaid expenses (net of provision for impairment Rs. 31.22 million (31 March 2024 - Rs. 31.22 million))	100.89	78.53	105.57	65.48
Advance to vendors	-	181.93	-	159.51
Taxes paid under protest	-	56.30	-	55.75
Receivable from revenue authorities	-	28.25	-	32.88
Unsecured, considered doubtful				
Capital advances #	8.13	-	8.70	-
Less: Allowance for bad and doubtful advances (refer note 30)	(8.13)	-	(8.70)	-
Less: Provision for impairment #	-	-	-	-
Advance to vendors	-	55.76	-	55.76
Less: Allowance for bad and doubtful advances	-	(55.76)	-	(55.76)
Total	404.84	345.01	433.34	313.62

* Refer note 18 for details of charge created on other current assets


Rs Nil million (31 March 2024 - 58.99 million) written-off during the year [refer note 5.2(i)]

11.1 During the previous year ended 31 March 2024, the Parties have decided not to pursue the aforementioned BTA as certain conditions precedent to the closing of the BTA could not be achieved. During the current year, the said amount adjusted against security deposit payable by the Company for the new lease agreement with the same party.

12 Inventories (lower of cost and net realisable value)*

	As at	
	31 March 2025	31 March 2024
Medical and non-medical items	530.23	426.68
Total	530.23	426.68

*Inventories are subject to charge to secure bank loans. There are nil provisions for written down to net realisable value.



13 Trade receivables (unsecured)*

	As at 31 March 2025	As at 31 March 2024
Billed - considered good		
Trade receivables - unsecured	4,610.81	3,385.81
Less: Loss allowance (refer note 40)	(792.39)	(685.61)
	3,818.42	2,700.20
Unbilled - considered good		
Trade receivables - unsecured	206.03	255.36
Less: Loss allowance (refer note 40)	(15.49)	(15.30)
	190.54	240.06
	4,008.96	2,940.26

*Trade receivables are subject to charge to secure bank loans
Refer note 43 for trade receivables from related parties

Trade receivables ageing schedule
As at 31 March 2025

Particulars	Unbilled	Billed - outstanding for following periods from due date					Total
		Less than 6 months	6 Months - 1 year	1-2 Years	2-3 Years	More than 3 years	
Undisputed Trade receivables - considered good	206.03	2,486.36	1,130.98	475.99	197.82	319.66	4,816.84
Undisputed Trade receivables - which have significant increase in risk	-	-	-	-	-	-	-
Undisputed Trade receivables - credit impaired	-	-	-	-	-	-	-
	206.03	2,486.36	1,130.98	475.99	197.82	319.66	4,816.84
Less: Loss allowance on trade receivables							(807.88)
Total							4,008.96

There are no disputed trade receivables as at 31 March 2025

As at 31 March 2024

Particulars	Unbilled	Billed - outstanding for following periods from due date					Total
		Less than 6 months	6 Months - 1 year	1-2 Years	2-3 Years	More than 3 years	
Undisputed Trade receivables - considered good	255.36	2,002.34	614.20	381.62	123.97	263.68	3,641.17
Undisputed Trade receivables - which have significant increase in risk	-	-	-	-	-	-	-
Undisputed Trade receivables - credit impaired	-	-	-	-	-	-	-
	255.36	2,002.34	614.20	381.62	123.97	263.68	3,641.17
Less: Loss allowance on trade receivables							(700.91)
Total							2,940.26

There are no disputed trade receivables as at 31 March 2024

The Group's exposure to credit risk is explained in Note 40.

14 Cash and cash equivalents

	As at 31 March 2025	As at 31 March 2024
A. Cash and cash equivalents		
(a) Cash on hand	22.95	10.76
(b) Cheques, drafts on hand	4.22	1.73
(c) Balance in bank		
In current accounts and in Exchange Traders Foreign Currency Account (EEFC) accounts	1,265.42	576.90
In deposit accounts with original maturity less than 3 months	1,066.12	2,136.74
Total	2,358.71	2,726.13

14.1 Bank balance other than cash and cash equivalents above

Deposits with banks with balance maturity of less than 12 months *	1,118.26	304.60
Bank balance other than cash and cash equivalents above	1,118.26	304.60

* Deposits include margin money deposits with banks and deposits given as security for obtaining bank guarantees. These deposits are restrictive.

For the purpose of the statement of cash flows, cash and cash equivalent comprise the following:

	As at 31 March 2025	As at 31 March 2024
(a) Cash on hand	22.95	10.76
(b) Cheques, drafts on hand	4.22	1.73
(c) Balance with bank		
In current accounts and EEFC accounts	1,265.42	576.90
In deposit accounts	1,066.12	2,136.74
Cash and cash equivalents as per balance sheet	2,358.71	2,726.13
Less: Bank overdrafts repayable on demand (Refer Note 18)	(2,829.34)	(1,065.95)
Cash and cash equivalents as per consolidated statement of cash flows	(470.63)	1,660.18



VH

	As at 31 March 2025	As at 31 March 2024
15 Equity share capital		
Authorised share capital:		
200,000,000 equity shares of Rs 10 each (as at 31 March 2024: 200,000,000 equity shares of Rs 10 each)	2,000.00	2,000.00
Issued, subscribed and paid up capital comprises:		
139,415,370 equity shares of Rs 10 each (as at 31 March 2024: 139,289,687)	1,394.16	1,392.90
All issued shares are fully paid up		
15.1 Reconciliation of the equity shares outstanding at the beginning and at the end of the year:		
	Number of shares	Amount
Balance as at 01 April 2023	139,116,062	1,391.16
Issue of equity shares pursuant to exercise of employee share options under the Employee Stock Option Scheme 2014 and Employee Stock Option Scheme 2021 (refer note 38(C))	173,625	1.74
Balance as at 31 March 2024	139,289,687	1,392.90
Issue of equity shares pursuant to exercise of employee share options under the Employee Stock Option Scheme 2014 and the Employee Stock Option Scheme 2021 (refer note 38(C))	125,683	1.26
Balance as at 31 March 2025	139,415,370	1,394.16

15.2 Rights, preferences and restrictions attached to equity shares
Fully paid equity shares, which have a par value of Rs 10, carry one vote per share and carry a right to dividends. The Company has only one class of equity share having a par value of Rs 10 - each. Holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of the equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amount. The distribution will be in proportion to number of equity shares held by the shareholders.

Employee stock options and terms attached to stock options granted to employees are described in Note 38.

15.3 Details of shareholder holding more than 5% shares of equity shares

Aceso Company Pte Ltd *
Dr B S Ajankumar

*Refer note 50

	As at 31 March 2025		As at 31 March 2024	
	Number of Shares held	% holding of equity shares	Number of Shares held	% holding of equity shares
Aceso Company Pte Ltd *	84,134,078	60.40%	84,134,078	60.40%
Dr B S Ajankumar	14,498,715	10.41%	14,498,715	10.41%

15.4 Shareholding of promoters and promoter group

Promoter

Aceso Company Pte Ltd
Dr B S Ajankumar

Promoter group *

Asmita Ajankumar
Agnika Ajankumar
Bhagya A Ajankumar
Amali Ajankumar Rossi

Refer note 50

	As at 31 March 2025		Percentage change during the year ended 31 March 2025
	Number of shares held	% holding of equity shares	
Aceso Company Pte Ltd	84,134,078	60.40%	0.00%
Dr B S Ajankumar	14,498,715	10.41%	0.00%
Asmita Ajankumar	327,259	0.23%	0.00%
Agnika Ajankumar	327,258	0.23%	0.00%
Bhagya A Ajankumar	1,795	0.00%	-
Amali Ajankumar Rossi	1,000	0.00%	-

Promoter

Aceso Company Pte Ltd
Dr B S Ajankumar

Promoter group *

Asmita Ajankumar
Agnika Ajankumar
Bhagya A Ajankumar
Amali Ajankumar Rossi

* Promoter group is as per the shareholding pattern filing made to Securities and Exchange Board of India (SEBI)

	As at 31 March 2024		Percentage change during the year ended 31 March 2024
	Number of shares held	% holding of equity shares	
Aceso Company Pte Ltd	84,134,078	60.40%	-2.49%
Dr B S Ajankumar	14,498,715	10.41%	(2.58%)
Asmita Ajankumar	327,259	0.23%	(0.01)%
Agnika Ajankumar	327,258	0.23%	(0.01)%
Bhagya A Ajankumar	1,795	0.00%	-
Amali Ajankumar Rossi	1,000	0.00%	-

15.5 Number of equity shares of Rs.10/- each reserved for issuance:

Particulars	As at 31 March 2025	As at 31 March 2024
To eligible employees under Employee Stock Option scheme (also refer note 38)	5,904,672	6,289,355

16 Other equity

Securities premium
Share options outstanding account
Capital reserve
Foreign currency translation reserve
Remeasurements of defined benefit plan
Retained earnings

Total

Note	As at 31 March 2025	As at 31 March 2024
16.1	11,719.84	11,688.73
16.2	223.55	175.55
16.3	6.77	6.77
16.4	(5.85)	(24.79)
16.5	(21.68)	(22.88)
16.6	(4,092.36)	4,962.48
Total	7,830.25	6,864.90

16.1 Securities premium

Balance at beginning of year
Premium on shares issued during year
Transferred to securities premium account on exercise of SOOs

Balance at end of year

	As at 31 March 2025	As at 31 March 2024
Balance at beginning of year	11,688.73	11,648.85
Premium on shares issued during year	14.32	17.75
Transferred to securities premium account on exercise of SOOs	(16.79)	22.13
Balance at end of year	11,719.84	11,688.73

16.2 Share options outstanding account

Balance at the beginning of the year
Transferred to Securities premium account on exercise of SOOs
Transferred to retained earnings on lapse of vested SOOs
Expense on employee stock option scheme (refer note 27)

Balance at end of year

Refer note 38

	As at 31 March 2025	As at 31 March 2024
Balance at the beginning of the year	175.55	120.28
Transferred to Securities premium account on exercise of SOOs	(16.79)	(22.13)
Transferred to retained earnings on lapse of vested SOOs	-	(1.06)
Expense on employee stock option scheme (refer note 27)	64.79	78.46
Balance at end of year	223.55	175.55

16.3 Capital reserve

Balance at beginning of year
Balance at end of year

	As at 31 March 2025	As at 31 March 2024
Balance at beginning of year	6.77	6.77
Balance at end of year	6.77	6.77

Vy.



16 Other equity (Contd.)

16.4 Foreign currency translation reserves

	As at 31 March 2025	As at 31 March 2024
Balance at beginning of year	(2,79)	(22,93)
Other comprehensive income / (loss) arising from exchange differences on translating the foreign operations	11,94	2,14
Balance at end of year	(5,85)	(20,79)

16.5 Remeasurements of the defined benefit liabilities

	As at 31 March 2025	As at 31 March 2024
Balance at beginning of year	(22,88)	(16,46)
Other comprehensive income / (loss) arising from remeasurement of defined benefit plan net of income tax	1,20	(6,42)
Balance at end of year	(21,68)	(22,88)

16.6 Retained earnings

	As at 31 March 2025	As at 31 March 2024
Balance at beginning of year	(4,962,48)	(4,522,45)
Profit attributable to owners of the Company	344,11	481,55
Written put option granted to NCI relating to acquisition of Vizag Hospital And Cancer Research Centre Private Limited (refer note 45.1)	(6,98,00)	-
Decognition of Put Option (refer note (ii) below)	1,06,00	-
Change in fair value of gross obligations over written put options issued to the non-controlling interests (refer note 45.1)	(26,00)	(90,00)
Transfer from Share options outstanding account on account of lapse of vested SOPs	-	1,06
Changes in ownership interests in subsidiaries that do not result in a loss of control (refer note (iii) below)	-	(832,64)
Balance at end of year	(4,092,38)	(4,962,48)

(i) The Company had issued written put option to non-controlling interests in HCG Medi-stage Hospitals Private Limited. In accordance with the terms of underlying shareholders agreement, should the option be exercised by non-controlling interests, the Company was required to settle such liability by payment of cash equivalent to such amount.

During the year ended 31 March 2025, the Company has entered into an Amended and Restated Shareholders' Agreement ("Restated SMA") on 14 February, 2025 with Aastha Oncology Private Limited ("AOPL") and HCG Medi-Stage Hospitals Private Limited ("Subsidiary"). The Restated SMA supersedes the shareholders' agreement dated 28 March 2012 entered into by and between the Company, AOPL, and the Subsidiary. The Restated SMA records the revised terms and conditions governing the management and governance of the Subsidiary, and the inter se rights and obligations between the Company and AOPL in respect of the Subsidiary. The Restated SMA also revises the terms of vest and the underlying Put Option with AOPL.

Pursuant to this amendment the Company has the option to settle put option granted to AOPL, at its sole discretion either by payment of equivalent cash or in the equity shares of the Company, at the fair value, accordingly the Company has decognised the put option liability amounting to Rs 1,06 million and credited Retained Earnings as per the relevant IndAS Standard 32 "Financial Instruments Presentation".

(ii) During the previous year ended 31 March 2024, the Company acquired the remaining non-controlling partnership interest aggregating to 49.5% in HCG Kolkata Cancer Care LLP (Formerly known as HCG KR Oncology LLP) as per the terms of Transfer of Partnership Interest Agreement dated 8 March 2024 for a consideration of Rs. 200 million.

(iii) During the previous year ended 31 March 2024, the Group acquired remaining non-controlling interest of 12.86% in HCG NCHRI Oncology LLP for a consideration of Rs. 264 million (including (a) Rs. 176 million pursuant to the Partnership Transfer Agreement ("PTA") with Dr. Arav Mehta and Dr. Sachitra Mehta, of which Rs. 134 million was paid and the balance consideration of Rs. 42 million was payable in 5 installments over the 18 month period as explained in note (b) Rs. 98 million pursuant to the Share Purchase Agreement with Nagpur Cancer Hospital & Research Institute Private Limited and its shareholders for its pre-existing stake in HCG NCHRI Oncology LLP (refer note 45.3). During the year ended 31 March 2025, the balance consideration of Rs. 42 million was paid by the group in accordance with the terms of the PTA.

17 Non-controlling interests

	As at 31 March 2025	As at 31 March 2024
Balance at the beginning of the year	393,38	88,91
Profit/(Loss) for the year	44,24	(68,21)
Other comprehensive income / (loss) for the year (net of tax)	1,87	(0,35)
Acquisition of subsidiaries (refer note 45.1)	236,56	-
Adjustment on account of change in holding without change in control (refer note 16.6 (ii))	-	373,00
Balance at the end of the year	676,05	393,38

Details of non-wholly owned subsidiaries that have material non-controlling interests

During the year ended 31 March 2025, the group has acquired Vizag Hospital And Cancer Research Centre Private Limited ("VHCRC") where the Company has material non-controlling interests. During the year ended 31 March 2024, there are no non-wholly owned subsidiaries that have material non-controlling interests. The management has set materiality at ten percent of the annual consolidated turnover, as per the last audited financial statements of the Company.

18 Borrowings

	As at 31 March 2025		As at 31 March 2024	
	Non Current	Current	Non Current	Current
Secured - at amortised cost				
(i) Term loans*				
from banks (Refer note 18.1.1)	5,875,96	916,78	4,663,55	656,76
(ii) Loans repayable on demand*				
from Banks (bank overdraft) (Refer note 18.1.3)	-	2,829,34	-	1,065,95
Unsecured - at amortised cost				
(i) Deferred payment liabilities (Refer note 18.1.2)	152,81	155,45	151,49	151,85
(ii) Loans from others (Refer note 18.1.2)	37,97	75,00	37,97	-
Total	6,045,84	3,976,47	4,853,01	1,874,56

* Includes interest accrued amounting to Rs. 21,88 million (31 March 2024: Rs. 11,30 million) relating to term loan from banks which is classified under the respective loans outstanding as on 31 March 2025 and 31 March 2024. The Group's exposure to liquidity risk is disclosed in Note 40.

VY.



18.1 Summary of borrowing arrangements

Details of security and terms of repayment of term loans and other loans (except loans repayable on demand) are stated below.

	As at 31 March 2025	As at 31 March 2024
Terms of repayment and security		
18.1.1 Term loans from banks - Secured		
Facility-1		
Non-current portion*	460.47	59.27
Amounts included under current borrowings	264.64	171.18
- Secured by exclusive charge on equipments purchased from these loans, first charge on immovable fixed assets (land and building) structures there upon and movable fixed assets (both present and future, not charged exclusively to any other lender) and second pari-passu charge on all current assets and receivables (both present and future) of the Company, HCG Oncology LLP, HCG Kolkata Cancer Care LLP (formerly known as HCG IRO Oncology LLP), HCG Manavata Oncology LLP and HCG Rajkot Hospitals LLP (formerly known as HCG San Hospitals LLP). - Rate of interest: Reporate + 3.25% p.a. and rate of interest 3 months MCLR + 0.20% p.a. - Repayable in installments over a period of 6 to 10 years after 1 to 3 year moratorium from the date of borrowing. * Non-current portion of bank debt as disclosed herein is gross of Rs 5.35 million towards unamortised loan processing charges, which is netted below (31 March 2024 of Rs. 4.04 million)		
Term loans from banks - Secured		
Facility-2		
Non-current portion*	1,348.57	956.96
Amounts included under current borrowings	201.04	145.45
- Secured by first pari-passu charge on movable fixed assets (both present and future, excluding those funded out exclusively by other lenders) and immovable fixed assets (land and building structures there upon) and second pari-passu charge by way of hypothecation on entire current assets of the Company, HCG Medisurge Hospitals Private Limited and HCG Oncology LLP. - Rate of interest: Reporate + 2.00% p.a. to 2.85% p.a. (31 March 2024: Rate of interest: Reporate + 2.30% p.a. to 2.85% p.a.) - Repayable in installments over a period of 6 to 9 years (including moratorium period of 12 months) from the date of borrowing. * Non-current portion of bank debt includes an amount of Rs. 19.15 million (31 March 2024: Rs. 14.08 million) towards unamortised loan processing charges, which is netted off below.		
Term loans from banks - Secured		
Facility-3		
Non-current portion *	1,387.20	1,110.00
Amounts included under current borrowings	184.39	90.55
Details of security and amount borrowed: - First pari-passu charge on movable fixed assets (both present and future, excluding those funded out exclusively by other lenders) and immovable fixed assets (land and building structures there upon) and ranking pari-passu charge with participating lenders. - Second pari-passu charge on all current assets and receivables both present and future with the first charge with working capital lenders. - Rate of interest: 1 year 1 bill + 1.68% p.a. to 1.77% p.a. (31 March 2024: Rate of interest: 3 Month 1 bill + 1.39% p.a.) - Repayable in installments over a period of 8 years from the date of borrowing. * Non-current portion of bank debt includes an amount of Rs. 17.03 million (31 March 2024: 19.46 million) towards unamortised loan processing charges, which is netted off below.		
Term loans from banks - Secured		
Facility-4		
Non-current portion *	413.28	472.76
Amounts included under current borrowings	59.67	76.93
Details of security and terms of repayment for the amounts borrowed: - Secured by hypothecation on the equipment finance. - Rate of interest: 1 year 1 bill + 1.34% to 1.57% p.a. (31 March 2024: Rate of interest: 3 Month 1 bill + 1.30% p.a.) - Repayable in installments over a period of 7 years from the date of borrowing. * Non-current portion of bank debt includes an amount of Rs. 10.05 million (31 March 2024: 11.71 million) towards unamortised loan processing charges, which is netted off below.		
Facility-5		
Non-current portion*	283.51	411.24
Amounts included under current borrowings	127.29	68.26
Details of security and terms of repayment for the amounts borrowed: - Extension of second charge over primary and collateral security for existing facilities and 100% credit guarantee by National Credit Guarantee Trustee Company Limited (NCGTC). - Rate of interest: Reporate + 1.90% p.a. to + 2.30% p.a. - Repayable in installments over a period of 3 years to 4 years from the date of borrowing excluding 2 years moratorium.		
Facility-6		
Non-current portion*	960.48	-
Amounts included under current borrowings	35.00	-
Details of security and terms of repayment for the amount borrowed during the current year: - Secured by first pari-passu charge on movable fixed assets (both present and future, excluding those funded out exclusively by other lenders) and immovable fixed assets (land and building structures there upon) and second pari-passu charge by way of hypothecation on entire current assets of the HCG NCHRI Oncology LLP. - Rate of interest: 1 year XLIB + 0.25% p.a. - Repayable in installments over a period of 8 years from the date of borrowing excluding 2 yrs of moratorium. * Non-current portion of bank debt includes an amount of Rs. 1.52 million (31 March 2024: Nil) towards unamortised loan processing charges, which is netted off below.		
Facility-7		
Non-current portion*	918.85	960.31
Amounts included under current borrowings	40.45	35.59
During the previous financial year, the existing loan was takeover by the new lender. While the terms of security remains the same, the rate of interest and the repayment tenure have been revised. - Secured by exclusive charge on all movable and immovable assets of Sushruti Health Care Solutions Limited. - Rate of interest: Reporate + 1.75% p.a. as at 31 March 2024. Reporate + 2.75% p.a. - Repayable in quarterly installments over a period of 10 years from the date of takeover.		
Facility-8		
Non-current portion	136.92	201.39
Amounts included under current borrowings	65.29	67.49
(Refer note 45.3) - Secured by exclusive charge on leasehold rights of plot/property located at Wamni Nagpur and exclusive charge on all movable fixed assets and current assets of Nagpur Cancer Hospital and Research Institute Private Limited. - Rate of interest: Reporate + 3.25% - Repayable in quarterly installments over a period of 12 years from the date of borrowing.		
Facility-9		
Non-current portion	52.80	-
Amounts included under current borrowings	-	1.51
- Secured by charge on all assets of Cancer Care Kuma Limited. - Rate of interest: Bank's variable Kewas Shillings base rate. - Repayable in installments over a period of 6 years from the date of borrowing.		
Less: Unamortised loan processing charges	(36.11)	(42.29)
Total term loans from bank - secured	6,791.94	5,320.31
Less: Amounts included under current borrowings	(916.78)	(656.76)
Non-current portion of bank borrowings	5,875.06	4,663.55

Vy.



18.1.2	Terms of repayment and security	As at 31 March 2025	As at 31 March 2024
	Term loans from others - Unsecured		
	Non-current portion		
	Amounts included under current borrowings	6.41	6.41
	- Interest free loan repayable as and when funds are available	-	-
	Non-current portion		
	Amounts included under current borrowings	31.56	31.56
	- Rate of interest: 10% p.a	-	-
	- Repayable in 9 half-yearly installments from April 2026	-	-
	Non-current portion		
	Amounts included under current borrowings	75.00	-
	- Rate of interest: 10% p.a	-	-
	- Repayable within 12 months from the date of disbursement and extendable on mutually agreed terms	-	-
18.1.3	Deferred payment liabilities - Unsecured		
	Non-current portion		
	Amounts included under current borrowings	132.81	151.49
	- Rate of interest: 3% to 10% p.a	155.45	151.85
	- Repayable over the period of 3 to 7 years	-	-

18.1.4	Terms of repayment and security	As at 31 March 2025	As at 31 March 2024
	Secured loan repayable on demand from banks:		
	Facility-1	2,797.78	1,914.22
	Secured by first pari-passu charge on entire current assets (both present and future), second pari-passu charge over entire fixed assets (both present and future other than exclusively charged) of the company		
	Rate of Interest: Repo rate + 1.70% p.a. to 2% p.a. MIBOR + 1.84% p.a., 1 year T bill + 1.52% p.a. to 1.65% p.a. (31 March 2024: Rate of Interest: 1 month MCLR + 0.35% p.a, 3 month T bill + 1.37% Repo + 1.90% p.a.)		
	Note: There are no material differences between the quarterly returns or statements filed by the Company for working capital limits with such banks and financial institutions and the books of account of the Company		
	Facility-2	31.56	51.73
	Secured by charge on all assets of Cancer Care Kenya Limited		
	Rate of interest: Bank's variable Kenyan Shillings base rate		
	Total	2,829.34	1,965.95

19 Other financial liabilities

	As at 31 March 2025		As at 31 March 2024	
	Non Current	Current	Non Current	Current
Gross obligation on written put option (refer note (i) below and refer note 45.1)	634.00	-	-	1,060.00
Forward Liabilities (refer note 45.1)	-	1,401.34	-	-
Creditors for capital goods	-	116.87	-	136.17
Contingent consideration (refer note 45.2)	-	-	-	27.82
Deferred Consideration (refer note (iii) below)	-	-	-	39.76
Accrued salaries and benefits	-	428.09	-	470.06
Others	-	12.90	-	2.70
Total	634.00	1,959.20	-	1,636.51

The Company's exposure to liquidity risk are disclosed in note 40

(i) Relates to gross obligation towards put option issued to non-controlling interest in Vizag Hospital and Cancer Research Centre Private Limited and HCG Medi-surge Hospitals Private Limited. Refer note 16.6 (i) and Refer note 45.1

(ii) During the previous year ended 31 March 2024, the Company had acquired remaining non-controlling interest in its subsidiary HCG NCLIRI Oncology LLP on 22 August 2023 pursuant to the Partnership Transfer Agreement ("PTA") with Dr. Ajay Mehta and Dr. Sachina Mehta dated 18 July 2023 for a consideration of Rs. 176 million, including deferred consideration of Rs. 42 million payable in 5 installments over the 18 month period. Of the total consideration, the Company had paid Rs. 134 million on 22 August 2023 and had recognised Rs. 2.12 million as interest on deferred consideration under the finance cost. During the year ended 31 March 2025 the balance consideration of Rs. 42 million was paid by the group in accordance with the terms of the PTA.

20 Other liabilities

	As at 31 March 2025		As at 31 March 2024	
	Non Current	Current	Non Current	Current
Advance from customers (refer note 48)	-	167.38	-	181.87
Balance due to statutory government authorities	-	140.69	-	107.83
Deferred government grant (refer note (i) below)	387.33	55.51	328.21	37.68
Provision for contingencies for duties and taxes (refer note (ii) below)	-	3.19	-	155.84
Total	387.33	366.97	328.21	482.62

Notes


(i) The Group imports medical equipments under Export Promotion Capital Goods (EPCG) scheme. Under the Scheme, as the Group expects to meet the specified criteria, it is exempt from paying customs duty on imports which is recognised as a government grant. Fair value of the government grant is capitalised along with the equipment. Similarly, receipt of any other government grant related to capital expenditure is capitalised along with the equipment. Deferred income is amortised over the useful life of the equipment it has procured.

Additional deferred government grant from EPCG recognised during the year ended 31 March 2025 is Rs. 125.94 million (31 March 2024: Rs. 19.58 million). Government grant income recognised during the year is Rs. 47.14 million (31 March 2024: Rs. 42.48 million). Further, the deferred government grant reduced by Rs. 126.60 million during the year ended 31 March 2025 pursuant to settlement of duties and taxes on account of payment. Rs. 8.75 million has been reduced on account of meeting export obligation and gain on settlement recorded amounting to Rs. 29.56 million on account of provision created for higher duty saved amount in earlier years. The same has been recorded under 'Other Income' amounting to Rs. 29.29 million (refer note 25). As at 31 March 2025 and 31 March 2024, for certain licenses there is unfulfilled condition with respect to government grant availed (refer note 33). The Group based its assessment, expects that it will be able to meet its export obligations.

(ii) For certain cases, the Group expects shortfall in meeting the export obligations required under the EPCG Scheme described above. Accordingly, provision for contingencies had been recognized towards estimated duties and taxes. Interest recognized during the year ended 31 March 2025 on provision for such duties and taxes is Rs. 3.24 million (31 March 2024: Rs. 12.44 million). During the year ended 31 March 2025 and 31 March 2024, the Group applied for closure of certain licenses pursuant to payment of required duties and taxes aggregating to Rs. 126.60 million (including interest of Rs. 62.60 million) and Rs. 231.46 million (including interest of Rs. 123.18 million), respectively. Refer note 28.

Disclosures relating to movement in EPCG provision	As at 31 March 2025	As at 31 March 2024
At the beginning of the year	155.84	374.87
Provision made / (written back) during the year	(17.32)	12.43
Payment / settlement made during the year	(135.33)	(231.46)
At the end of the year	3.19	155.84

V9.



21 Provisions

Employee benefits

Gratuities (Refer note 37.2)

Compensated absences

Others

Provision for indemnified tax disputes

Total

	As at 31 March 2025		As at 31 March 2024	
	Non Current	Current	Non Current	Current
Gratuities (Refer note 37.2)	191.21	66.50	156.62	59.20
Compensated absences	25.15	77.4	-	72.96
Others	-	50.00	-	50.00
Provision for indemnified tax disputes	-	-	-	50.00
Total	214.34	193.54	156.62	182.86

22 Trade Payables*

Total outstanding dues of micro enterprises and small enterprises (refer note 42)

Total outstanding dues of creditors other than micro enterprises and small enterprises

Total

	As at As at 31 March 2025	As at 31 March 2024
Total outstanding dues of micro enterprises and small enterprises (refer note 42)	41.78	62.12
Total outstanding dues of creditors other than micro enterprises and small enterprises	3,301.21	2,748.53
Total	3,342.99	2,810.65

* for details related to payable to related parties - refer note 43

Trade payables ageing schedule

Particulars

Particulars	As at 31 March 2025		
	Micro enterprises and small enterprises	Others	Total
Unbilled dues	1.43	1,144.42	1,145.85
Outstanding for following periods from due date of payment			
Not yet due	15.88	883.16	899.04
Less than 1 year	24.37	1,093.62	1,117.99
1-2 years	-	116.15	116.15
2-3 years	-	15.03	15.03
More than 3 years	-	48.83	48.83
Total	41.38	3,301.21	3,342.59

There are no disputed dues as at 31 March 2025

Particulars

Particulars	As at 31 March 2024		
	Micro enterprises and small enterprises	Others	Total
Unbilled dues	1.34	1,014.74	1,016.08
Outstanding for following periods from due date of payment			
Not yet due	40.16	516.30	556.46
Less than 1 year	20.45	1,019.41	1,039.86
1-2 years	0.17	115.79	115.96
2-3 years	-	27.04	27.04
More than 3 years	-	55.25	55.25
Total	62.12	2,748.53	2,810.65

There are no disputed dues as at 31 March 2024

Vy.




	For the year ended 31 March 2025	For the year ended 31 March 2024
23 Revenue from operations (refer note 48)		
Revenue from contract with customers		
(a) Income from medical services	20,563.17	17,961.47
(b) Sale of medical and non-medical items	1,445.27	937.61
(c) Other operating revenues	172.92	179.63
Total	22,181.36	19,078.71
24 Income from government grant		
Income from government grant	47.14	42.48
Total	47.14	42.48
25 Other income		
Interest on financial assets at amortised cost (refer note below)	134.90	94.20
Interest on income tax refund	23.92	32.77
Net foreign exchange gains	0.79	4.46
Net gain on financial assets designated at fair value through profit and loss	1.57	2.17
Payables no longer required written-back	-	6.41
Reversal of contingent consideration	27.82	-
Gain on termination of lease	16.24	17.57
Miscellaneous income	148.90	11.84
Total	348.14	169.42
Note:		
Interest on financial assets at amortised cost comprise:		
Interest on bank deposits	108.72	79.80
Interest on financial assets at amortised cost	26.18	23.40
Total	134.90	94.20
26 Changes in inventories		
Inventories at the beginning of the year	426.66	382.86
Inventories at the end of the year	530.23	426.66
Net (decrease)	(103.57)	(43.80)
Acquired through Business Combinations (Refer note 45.1 and 45.2)	7.40	4.31
Changes in inventories	(96.17)	(39.49)
27 Employee benefits expense		
Salaries and wages	3,115.79	2,673.63
Contribution to provident and other funds (Refer note 37)	187.22	170.21
Expense on equity-settled share-based payment transactions (Refer note 16.2 and 38), net	64.79	78.46
Staff welfare expenses	166.95	160.12
Total	3,534.75	3,082.42
28 Finance costs		
(a) Interest expense on financial liabilities measured at amortised cost:		
Interest on term loans from banks and others	533.00	389.27
Interest on bank overdraft	140.67	35.46
Interest on deferred payment obligations	17.23	15.25
Provision for contingency	3.24	12.43
Interest on forward liability	53.88	-
Interest on deferred consideration and contingent consideration	1.39	3.64
	749.41	456.05
(b) Interest expense on lease liabilities		
Interest expense on lease liabilities (Gross)	806.82	540.96
Less: Capitalised in capital work-in-progress	(109.96)	(5.25)
Interest expense on lease liabilities (net)	696.86	535.71
(c) Others		
Interest on defined benefit obligations	18.32	15.18
Net loss on foreign currency borrowings to the extent regarded as borrowing costs	3.73	3.81
Other borrowing costs	77.29	76.61
Total	1,545.61	1,087.36
29 Depreciation and amortisation expense		
Depreciation of property, plant and equipment (refer note 5)	1,278.06	1,092.11
Depreciation of right-of-use assets, Gross (refer note 6)	787.43	580.14
Less: Capitalised in capital work-in-progress	(80.69)	(5.94)
Depreciation of right-of-use assets, net	706.74	574.20
Amortisation of intangible assets (refer note 7)	128.64	77.25
Total	2,113.44	1,743.56

V.S.



	For the year ended 31 March 2025	For the year ended 31 March 2024		
30 Other expenses				
Medical consultancy charges	4,816.73	4,135.70		
Lab charges	213.16	210.02		
Power and fuel & water charges	439.66	393.49		
House keeping expenses	406.97	362.41		
Rent (refer note 6)	269.37	218.40		
Repairs and maintenance				
Building	37.36	23.93		
Machinery	511.93	471.81		
Office maintenance & Others	410.27	298.23		
Insurance	45.55	27.55		
Rates and taxes	235.84	197.56		
Printing & stationery	74.74	68.99		
Advertisement, publicity & marketing	462.65	401.24		
Travelling & conveyance	197.01	183.57		
Legal & professional fees	469.67	564.56		
Payment to auditors	28.43	24.14		
Telephone expenses	57.57	62.46		
Trade receivable written off, net (note-40)	97.27	4.32		
Loss allowance on trade receivables (net of reversal) (refer note 40)	106.97	225.61		
Loss on disposal of property, plant and equipment	10.64	17.74		
Corporate social responsibility	19.77	5.33		
Miscellaneous expenses	103.36	91.68		
Total	9,014.92	7,988.74		
31 Exceptional items				
Project cost no longer required written-back				
Privat project (refer note 5.2(i))	-	39.05		
Total	-	39.05		
32 Income tax expense				
32.1 Income tax recognised in the Statement of profit and loss				
Current tax				
Current tax	286.63	343.15		
Deferred tax expense/ (credit)				
- Deferred tax (credit)	(205.33)	(79.20)		
Total income tax expense recognised in the Statement of profit and loss	81.30	263.95		
The reconciliation between the income tax expense of the Group and amounts computed by applying the Indian statutory income tax rate to profit before taxes is as follows:				
Profit before tax	569.64	677.29		
Enacted income tax rate in India	25.17%	25.17%		
Computed expected tax expense	143.38	170.47		
Effect of:				
Permanent differences and others	97.23	22.39		
Share of loss from subsidiaries and associate on which deferred tax asset is not recognised	30.00	73.10		
Deferred tax recognition (reversal) on the brought forward losses in subsidiaries	(186.81)	-		
Differences of tax rates in subsidiaries and joint venture	(2.50)	(2.01)		
	81.30	263.95		
* The Company has exercised the option permitted under section 115BAA of the Income-tax Act, 1961, as introduced by the Taxation Laws (Amendment) Ordinance, 2019, with effect from the financial year 2023-24. Accordingly, the Company has continued to recognise deferred taxes based on the rates applicable for the years in which the deferred taxes are expected to be realised/settled.				
32.2 Income tax recognised in other comprehensive income / (loss)				
Income tax arising on income and expenses recognised in other comprehensive income / (loss):				
Remeasurement of defined benefit obligation	(2.86)	1.55		
Total income tax recognised in other comprehensive income / (loss)	(2.86)	1.55		
32.3 Net deferred tax Assets and liabilities				
Deferred tax balances				
Deferred tax assets	As at 31 March 2025	As at 31 March 2024		
Deferred tax liabilities	249.93	70.58		
Net	(35.35)	(60.75)		
	214.58	9.83		
Significant components of net deferred tax assets and liabilities for the year ended 31 March 2025 are as follows:				
Deferred tax assets / (liabilities) in relation to	Opening Balance	Recognised in statement of profit and loss	Recognised in other comprehensive income	Closing Balance
Property, plant and equipment and intangible assets	(514.32)	8.77	-	(505.55)
Right-of-use assets	(843.59)	(552.87)	-	(1,396.46)
Goodwill	(169.55)	-	-	(169.55)
Sec 43B items	82.22	(1.51)	2.86	83.57
Provision for doubtful debts/advances	188.34	(52.61)	-	135.73
Tax losses	20.29	186.81	-	207.10
Lease liabilities	1,208.47	531.31	-	1,739.78
Financial assets at amortised cost	(64.37)	89.93	-	25.56
Others	102.34	(4.50)	-	97.84
Total	9.83	205.33	2.86	214.58



Net deferred tax Assets and liabilities (Contd.,)

Significant components of net deferred tax assets and liabilities for the year ended 31 March 2024 are As follows:

Deferred tax assets / (liabilities) in relation to	Opening balance	Recognised in statement of profit and loss	Recognised in other comprehensive income	Closing balance
Property, plant and equipment and intangible assets	(524.47)	10.15	-	(514.32)
Right-of-use assets	(681.09)	(162.50)	-	(843.59)
Goodwill	(169.55)	-	-	(169.55)
Sec 43B items	72.91	7.76	1.55	82.22
Provision for doubtful debts/advances	142.39	45.95	-	188.34
Tax losses	17.85	2.44	-	20.29
Lease liabilities	940.43	268.04	-	1,208.47
Financial assets at amortised cost	31.95	(96.32)	-	(64.37)
Others	98.66	3.68	-	102.34
Total	(70.92)	79.20	1.55	9.83

Unrecognised deferred tax assets: Deferred tax assets in respect of certain subsidiaries have not been recognised in respect of the following items, because it is not probable that future taxable profit will be available against which the Group can use the benefits therefrom

	As at 31 March 2025		As at 31 March 2024	
	Gross amount	Unrecognised tax effect *	Gross amount	Unrecognised tax effect *
Deductible temporary differences	2,334.39	774.93	821.26	286.98
Tax losses	2,763.17	893.72	2,046.99	715.30
	5,097.56	1,668.65	2,868.25	1,002.28

* At applicable rate for respective entities

Tax losses for which no deferred tax asset was recognised expire as follows

	As at 31 March 2025		As at 31 March 2024	
	Amount	Expire during	Amount	Expire during
Expire	928.53	2026-2033	1,119.78	2025-2032
Never expire	1,834.64		927.21	

Unrecognised deferred tax liabilities: As at 31 March 2025, there was a deferred tax liability of Rs 343.186 million (31 March 2024: Rs 203.96 million) in respect of temporary differences of Rs 1363.59 million (31 March 2024: Rs 810.40 million) related to investments in subsidiaries. However, this liability was not recognised because the Group controls the dividend policy of its subsidiaries i.e. the Group controls the timing of reversal of the related taxable temporary differences and management is satisfied that they will not reverse in the foreseeable future.

32.4 Other tax assets (net)

Tax deducted at source, advance tax (net of Provision)

	As at 31 March 2025	As at 31 March 2024
	855.38	769.69
	855.38	769.69

32.5 Current tax liabilities (net)

Provision for tax, (net of advance tax, tax deducted at source)

	As at 31 March 2025	As at 31 March 2024
	26.37	21.98
	26.37	21.98

33 Contingent liabilities

Particulars

Claims against the Group not acknowledged as debt relating to

	As at 31 March 2025	As at 31 March 2024
Customs duty (Refer note (i) below)	4.48	4.48
Excise and service tax (Refer note (ii) below)	31.72	31.72
Value added tax (Refer note (iii) below)	49.03	49.97
Sales tax (Refer note (iv) below)	26.00	26.00
Goods and Services Tax (Refer note (v) below)	-	16.44
Income tax (Refer note (vi) below)	33.37	33.37
Duties and taxes in respect of EPCG licenses (Refer note (vii) below)	517.58	544.38
Bonus to employees pursuant to retrospective Amendment to the Payment of Bonus Act, 1965 (Refer note (viii) below)	9.98	9.98
Other claims against the Group by its former employees, not acknowledged as debt (Refer note (ix) below)	17.15	17.15

Pending resolution of the respective proceedings, it is not practicable for the Group to estimate the timings of cash outflows, if any, in respect of the above as it is determinable only on receipt of judgements/decisions pending with various forums/authorities.

Notes:

(i) HCG Medisurge Hospitals Private Limited (HCG Medisurge) imported radiation equipment, Linear Accelerator-True Beam with standard accessories in two consignments. First consignment with main Linear Accelerator equipment was cleared by paying CVD @ 5% and second consignment was cleared as accessories of the medical equipment with Nil rate of CVD by claiming benefit under Notification No.06/2006 dated 01.03.2006. The Commissioner of Customs has passed the order against the import of the second consignment as "Accessories spare parts of Linear Accelerator" which attracts CVD @ 5% and declined the benefit of Notification No. 06/2006 and levied duty of Rs 2.24 million and penalty of Rs 2.24 million along with applicable interest. The HCG Medisurge has appealed before Customs, Excise & Service Tax Appellate Tribunal, Mumbai and is positive of claiming benefit under said notification.

(ii) (a) Excise Commissionerate-III, Bengaluru has passed Order against the Company adjudicating that the product Fluro-deoxy-glucose (FDG) is excisable and levied excise duty for the period under scrutiny from April 2009 to March 2014 of Rs 6.80 million, interest on duty amount, penalty of Rs 6.80 million, redemption fine of Rs 0.6 million in lieu of confiscation of goods not available. The order also imposed a penalty of Rs 1 million on Dr. B.S. Ajakumar, Chairman of the Company. The Company has filed an appeal before CESTAT by paying Central Excise Duty of Rs 0.6 million.

(ii) (b) Additional Commissionerate of Central Excise, Chennai, has passed the Order confirming the excisability on sale of FDG for the period March 2013 to June 2015 levying excise duty of Rs 6.57 million, interest on duty amount and penalty of Rs 6.57 million. If it is excisable the same has to be classified under Chapter 30 which attracts excise duty at 6% and valuation of captively consumed FDG will reduce the demand. The Group is positive of winning the case on the ground that FDG is not excisable as there is no specific entry in the Central Excise Tariff Act 1985.

(ii) (c) HealthCare Global Senthil Multispecialty Hospitals Private Limited (HCG-Senthil), has undergone service tax audit for the period 2008-09 to 2012-13 and noted that during the period July 2010 to April 2011, medical services provided to TPA are chargeable to service tax for which a demand of Rs 2.09 million is raised for short payment of service tax. Also purchase volume discount has been classified as business auxiliary services for which a demand of Rs 1.29 million has been raised by Joint Commissioner, Salem. HCG-Senthil appealed before Commissioner of Central Excise (Appeals) where the order was passed in favour of Revenue. Subsequently, the Company has filed an appeal before CESTAT, Chennai.

The HCG-Senthil has served to the patrons under Tamil Nadu Government Scheme and the settlement is done by TPA, which is exempt from Service tax and purchase volume discount has been wrongly categorised as business auxiliary service which is out of the ambit of Service tax. Hence the HCG-Senthil believes there would be no service tax liability.



V4

33 Contingent liabilities (Contd.,)

(iii) (a) HealthCare Global Vijay Oncology Private Limited is merged with Company effective from 1 April 2015, has undergone departmental VAT audit for the period from 2011-12 to 2014-15 and noted that the Company has not charged and paid VAT on supply of food to patients and raised a AP-VAT demand of Rs 2 million. Further, the Deputy Commercial Tax Officer, Vijayawada has passed the penalty order for Rs 0.5 million against the above AP-VAT audit order. The Company has filed an writ petition before Andhra Pradesh High Court by paying Rs 0.4 million VAT amount to department.

The Company is positive of winning the case on the ground that various High Courts in India have ruled that the supply of food to patient is pursuant to provision of medical service and is not sale of goods.

(iii) (b) HCG Medisurge Hospitals Private Limited's (HCG Medisurge) VAT Assessment has been done for FY 2011-12 and noted that HCG Medisurge has not paid VAT totalling Rs 9.49 million on goods which HCG Medisurge claimed as Exempted goods. The AO has levied interest of Rs 4.56 million and penalty of Rs 1.64 million by wrongly assessing service income as a taxable item and levying VAT on cafeteria which was offered by HCG Medisurge to VAT under different VAT registration.

HCG Medisurge has filed an appeal before the Joint Commissioner of Commercial Taxes producing the relevant supporting documents for supply of exempted goods, provision of medical Services and offering of cafeteria sales under different VAT registration number. HCG Medisurge believes that the VAT demand will be dropped and no adverse effect on financial statement.

HCG Medisurge's VAT Assessment has been done for FY 2013-14, FY 2014-15 and 2015-16 wherein demand of Rs 0.94 million, Rs 1.18 million and Rs 0.48 million has been raised. The only issue in the order is that ITC is being disallowed. During the current year, demand raised for VAT assessment of FY 2013-14 has been paid by the company and the assessment is closed.

HCG Medisurge has filed an appeal before the Joint Commissioner of Commercial Taxes which is pending. HCG Medisurge has all the relevant documents to substantiate its claim for ITC. HCG Medisurge believes that the VAT demand will be dropped and no adverse effect on financial statement.

(iii) (c) HealthCare Global Enterprises Limited assessment for Karnataka Value Added Tax (VAT) has been done for FY 2013-14 to FY 2016-17 wherein demand of Rs 33.02 million has been raised. The demand has mainly arisen on account of differential rate of tax on canteen income, denial of input credit, wrongly taxing other income and ignoring the details of sales - sales returns. The entire demand has been recovered from the Company. Presently, appeals for FY 2015-16 and FY 2016-17 are pending before the Joint Commissioner, Department of Commercial Taxes.

With respect to FY 2013-14 and 2014-15, the appeal filed by the Company before Karnataka Appellate Tribunal (KVAT Tribunal) was dismissed ex-parte by the KVAT Tribunal due to non-appearance of the Company's counsel, vide Order dated 14 July 2022. However, the Company could not be present on the date of hearing nor make any representation as both the Company and its Counsel did not receive any intimation regarding the hearing. Subsequently, in December 2022, the Company has filed an application before the KVAT Tribunal for restoration of the appeal. KVAT Tribunal vide order dated 03 April 2023 allowed the application and restored the appeal to its original form.

The Company believes that the VAT demand will be dropped and there would be no adverse impact in the financial statements.

(iii) (d) Gujarat Value Added Tax (VAT) assessment has been closed for FY 2014-15, FY 2015-16 and FY 2016-17 wherein demand of Rs 7.84 Million, Rs 3.58 million and Rs 1.52 million have been raised. The Company being aggrieved, has filed an appeal for the above years on the ground that Sales Tax is not applicable on IP sales and there is no mismatch in ITC taken by the Company. The Company has paid Rs 1.30 million as pre-deposit against these orders. Currently, the appeal against the order is pending before the Deputy Commissioner of State Tax.

(iv) HealthCare Global Enterprises Limited assessment for Central Sales Tax (CST) has been done for FY 2014-15, FY 2015-16 and FY 2016-17 wherein demand of Rs 9.46 million was raised. The demand has mainly arisen on account of non-submission of 'F' Forms before the AO. Though, demand has arisen, it is to be noted that the transactions has been reported correctly and it is more a procedural challenge leading to the demand. Entire demand has been recovered from the Company. Currently, the cases are pending before the Deputy Commissioner of Commercial Taxes. The Group does not expect any adverse impact on the consolidated financial statements.

(v) GST demand of Rs 6.95 million had been raised against the Company on corporate guarantee services provided to its subsidiaries for the financial year 2017-18. The Company had filed an appeal before the appellate authority. Further, GST demand of Rs 9.49 million had been raised against HCG Oncology Hospitals LLP alleging incorrect input credit claimed during the financial year 2019-20. Appeal had been filed before the appellate authority in earlier years. The Group received a favourable order against these both the GST demands and these cases were closed during the current year.

(vi) (a) During the financial Year 2011-12, HCG Medisurge had made payment to Aastha Oncology Private Limited towards their medical / professional consultancy services after deducting TDS @ 2% (Sec 197 certificate issued for Rs 31 Million) and thereafter @ 10% under Section 194J. However, the AO has erred in arriving at the total amount paid payable to Aastha Oncology Private Limited due to not considering the revised quarterly e-TDS return amount while making TDS assessment and has levied short payment of TDS of Rs 1.51 million and interest of Rs 1.23 million. HCG Medisurge has produced the supporting documents during appeal and also accepted a short payment of TDS after considering all transactions with Aastha Oncology Private Limited amounting to Rs 0.02 million. The Group does not expect an adverse impact on the consolidated financial statements.

(vi) (b) Contingent liability of Rs 30.63 million relates to possible claim against the Company with respect to disallowance of expenditure relating to capital projects which have been abandoned. Having regard to various judicial decisions on the similar matters, the management including its tax advisors expect that its position will likely be upheld on ultimate resolution. Further, against few other allowances / disallowances, there could be possible claims which management does not expect to be material.

(vii) The Group has availed benefit of custom duties on import of capital goods through Export Promotion and Capital Goods (EPCG) licenses against export obligations to be fulfilled within stipulated time period as per Foreign Trade Policy. The EPCG amount represents the duty benefits availed and currently pending to be settled across the Group.

(viii) The Payment of Bonus (Amendment) Act, 2015 has been enacted on 31 December 2015 with the retrospective effect from 01 April 2014. The Group has taken a position that the stay granted by the two High Courts of India on the retrospective application of the amendment would have a persuasive effect even outside the boundaries of the relevant states and accordingly, no provision for the year ended 31 March 2015 of Rs 9.98 million is required.

(ix) Certain former employees of the Group's overseas subsidiaries have raised claims demanding additional compensation for termination of their employment contracts. The management reasonably expects that these disputes, when ultimately concluded and determined, will not have any material adverse effect on the consolidated financial statements.

(x) The Hon'ble Supreme Court has, in a recent decision dated 28 February, 2019, ruled that special allowance would form part of wages for computing the Provident Fund (PF) contribution. The Group keeps a close watch on further clarifications and directions from the respective department based on which suitable action would be initiated, if any.

(xi) The Group is involved in other disputes, law suits and other claims including commercial matters which arise from time to time in the ordinary course of business. The Group believes that there are no such pending matters that are expected to have any material adverse effect on the consolidated financial statements.



Vy.

34 Commitments	As at	
	31 March 2025	31 March 2024
Particulars		
Estimated amount of contracts remaining to be executed on capital account and not provided for	1,975.24	872.20
Lease commitments (refer note 6)	239.85	2920.58

35 Earnings per share

The calculations of profit attributable to equity shareholders and weighted average number of equity shares outstanding for purposes of basic earnings and diluted earnings per share calculations are as follows:

35.1 Basic earnings per share

	For the year ended	For the year ended
	31 March 2025	31 March 2024
Profit for the year attributable to owners	444.10	481.55
Profit used in the calculation of basic earnings per share	444.10	481.55
Weighted average number of equity shares for the purposes of basic earnings per share	139,381,977	139,237,131
Basic earnings per equity share of Rs. 10 each (Amount in Rs.)	3.19	3.46

35.2 Diluted earnings per share

Profit used in the calculation of basic earnings per share	444.10	481.55
Profit used in the calculation of diluted earnings per share	444.10	481.55
Weighted average number of equity shares used in the calculation of diluted earnings per share	141,492,711	140,406,337
Diluted earnings per equity share of Rs. 10 each (Amount in Rs.)	3.14	3.43

The weighted average number of equity shares for the purpose of diluted earnings per share reconciles to the weighted average number of equity shares used in the calculation of basic earnings per share as follows:

Weighted average number of equity shares used in the calculation of basic earnings per share	139,381,977	139,237,131
Shares deemed to be issued for no consideration in respect of employee stock options and warrants	2,110,734	1,169,206
Weighted average number of equity shares used in the calculation of diluted earnings per share	141,492,711	140,406,337

36 Segment information

Ind AS 108 "Operating Segment" ("Ind AS 108") establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the "management approach" as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The CODM evaluates the Company's performance and allocates resources on overall basis. The Company's sole operating segment is therefore "Medical and Healthcare Services". Accordingly, there are no additional disclosures to be provided under Ind AS 108, other than those already provided in the financial statements.

Geographical information

Geographical information analyses the group's revenue and non-current assets by the group's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been presented based on the geographical location of the customers and segment assets has been presented based on the geographical location of the assets.

(i) Revenue from operations

Particulars	For the year ended	For the year ended
	31 March 2025	31 March 2024
India	21,748.22	18,898.41
Outside India	433.14	180.30
Total	22,181.36	19,078.71

(ii) Non-current assets*

Particulars	As at	
	31 March 2025	31 March 2024
India	25,489.37	19,196.76
Outside India	480.37	453.32
Total	25,969.74	19,650.08

*Non-current assets exclude financial assets and deferred tax assets



Vy.

37 Employee benefit plans

37.1 Defined contribution plans

The Group has defined contribution plan in form of Provident Fund and Employee State Insurance Scheme for qualifying employees. Under the Schemes, the Group Companies contribute a specified percentage of the payroll costs to fund the benefits. The total expense recognised in the Statement of profit and loss under employee benefit expenses in respect of such schemes are given below:

Particulars	For the year ended 31 March 2025	For the year ended 31 March 2024
Contribution to Provident Fund included under contribution to provident and other funds	148.32	159.08
Contribution to Employee State Insurance Scheme, included under staff welfare expenses	10.30	10.99
	<u>158.62</u>	<u>150.07</u>

37.2 Defined benefit plans

The Group offers gratuity plan for its qualified employees which is payable as per the requirements of Payment of Gratuity Act, 1972. The benefit vests upon completion of five years of continuous service and once vested it is payable to employees on retirement or on termination of employment. In case of death while in service, the gratuity is payable irrespective of vesting.

Amounts recognised in consolidated statement of profit and loss in respect of this defined benefit plan are as follows:

	For the year ended 31 March 2025	For the year ended 31 March 2024
Service cost recognised in employee benefits expense in note 27	38.90	31.13
Net interest expense recognised in finance costs in note 28	18.32	15.18
Components of defined benefit costs recognised in the Statement of profit and loss	<u>57.22</u>	<u>46.31</u>
Remeasurement of the net defined benefit plan:		
Actuarial losses arising from changes in demographic assumptions	-	-
Actuarial gains arising from changes in financial assumptions	4.86	1.91
Actuarial losses arising from experience adjustments	(8.92)	6.06
Remeasurement of the net defined benefit plan recognised in other comprehensive income	<u>(4.06)</u>	<u>7.97</u>

The amount included in the consolidated balance sheet arising from the entity's obligation in respect of its defined benefit plans is as follows:

	As at 31 March 2025	As at 31 March 2024
Present value of funded defined benefit obligation	273.81	218.14
Fair value of plan assets	16.10	1.62
Unfunded status	<u>257.71</u>	<u>216.52</u>
Net liability arising from defined benefit obligation	<u>257.71</u>	<u>216.52</u>
Non-current (refer note 21)	191.21	156.62
Current (refer note 21)	66.50	59.90

Movements in the present value of the defined benefit obligation are as follows:

	As at 31 March 2025	As at 31 March 2024
Opening defined benefit obligation	218.14	183.89
Acquisition of Business (refer note 45.1)	31.89	-
Current service cost	38.90	31.13
Interest cost	18.32	15.27
Remeasurement (gains)/losses:		
Actuarial gains arising from changes in financial assumptions	4.86	1.91
Actuarial losses arising from experience adjustments	(8.92)	6.06
Benefits paid	(29.37)	(20.12)
Closing defined benefit obligation	<u>273.81</u>	<u>218.14</u>

Movements in the fair value of the plan assets are as follows:

	Year ended 31 March 2025	Year ended 31 March 2024
Opening fair value of plan assets	1.62	1.53
Contribution to fund	0.98	-
Interest income	1.09	0.11
Acquisition of Business (refer note 45.1)	13.14	-
Benefit payments from the fund	(0.70)	-
Excess return over interest income on plan assets	(0.03)	(0.02)
Closing fair value of plan assets	<u>16.10</u>	<u>1.62</u>



Vy.

37.2 Defined benefit plans (Contd.,)

The fair value of the plan assets at the end of the reporting period for each category, are as follows

	Fair value of plan assets as at	
	31 March 2025	31 March 2024
Insurer-managed funds	16.10	1.62
Total	16.10	1.62

Plan assets consists of assets held in a 'long-term benefit fund' for the sole purpose of making future benefit payments when they fall due. Plan assets include qualifying insurance policies and are not quoted in the market.

The actual return on plan assets was Rs. 1.09 million (for the year ended 31 March 2024: Rs. 0.09 million).

Significant actuarial assumptions for the determination of the defined obligation are discount rate, expected salary increase and employee attrition. The sensitivity analyses below have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

The sensitivity of the defined benefit obligation to changes in the weighted principal assumptions is:

Particulars	31 March 2025		31 March 2024	
	Increase	Decrease	Increase	Decrease
Discount rate (1% movement)	(11.75)	13.32	(6.03)	6.42
Future salary increase (1% movement)	20.97	(19.01)	13.91	(12.67)
Attrition rate (10% movement)	(4.14)	4.45	(2.78)	2.97

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

The average duration of the benefit obligation at 31 March 2025 is 6.02 years (as at 31 March 2024 is 5.09 years).

The principal assumptions used for the purposes of the actuarial valuations were as follows.

	Valuation as at	
	31 March 2025	31 March 2024
Discount rate(s)	6.40% to 6.90%	6.90% to 7.00%
Expected rate(s) of salary increase	5.00% to 11.60%	5.00% to 7.50%
Rate of return on plan assets	6.25% to 9.60%	7.34% to 7.50%
Mortality table	I.A.M. 2012-14	I.A.M. 2012-14
Employee turnover rate	3.00% to 30.00%	13.40% to 30.00%

Each actuarial assumption made in the measurement of the defined benefit obligation is a source of risk. There are additional risks which can have an adverse impact on the plan, but are not allowed for in the measurement of the defined benefit obligation, such as liquidity and counterparty default risks. Some of the most significant risks are listed below.

Discount rate: Variations in discount rate don't affect the level of benefits under the plan. However, it is still a very significant assumption as it does affect the discount due to time value of money. A fall in discount rate will increase the present value of the obligation.

Salary increases: Since the plan benefits are linked to final salary, higher than expected salary increases will increase the cost of benefits under the plan. An increase in the salary escalation assumption will increase the present value of the obligation.


Attrition rates: Deviations in actual attrition experience compared to the attrition assumption will change the level of benefits and therefore the cost of those benefits. A change in the attrition assumption will also affect the present value of the obligation.

Regulatory risk: Since the minimum benefits under the plan are set by law, there is risk that a change in law could require the employer to pay higher benefits, increasing the cost as well as the present value of obligation.

Maturity profile of defined benefit obligation:

Particulars	As at	As at
	31 March 2025	31 March 2024
Within 1 year	69.25	61.48
1-2 year	54.21	46.24
2-3 year	45.30	38.05
3-4 year	36.43	31.39
4-5 year	28.50	24.82
5-10 year	70.44	55.89
> 10 years	126.07	15.61

V4.



38 Share-based payments

A Employee share option plan of the Company

(a) ESOP 2014

Pursuant to the shareholders' approval in the extraordinary general meeting held on 28 March 2014, the Board of Directors formulated the Scheme titled "Employee Stock Option Scheme 2014" (ESOP 2014). The ESOP 2014 allows the issue of options to employees of the Company and its subsidiaries. Each option comprises one underlying equity share.

As per the Scheme, the Remuneration Committee grants the options to the employees deemed eligible. The Exercise Price shall be a price that is not less than the face value per share per option. Options Granted under ESOP 2014 would vest not less than one year and not more than five years from the date of Grant of such Options. Vesting of Options would be a function of continued employment with the Company (passage of time) and achievement of performance criteria as specified by the Nomination and Remuneration Committee as communicated at the time of grant of options. The option holders may exercise those options vested within a period as specified which may range upto 10 years from the date of grant.

Upon ESOP 2021 becoming effective, no further stock option grants will be made under ESOP 2014. However, all the employee stock options already granted under this Scheme shall be eligible for being vested and exercised as per the terms of ESOP 2014.

(b) ESOP 2021

Pursuant to the shareholders' approval vide their special resolution passed through postal ballot on 23 May 2021, the Board of Directors formulated the Scheme titled "Employee Stock Option Scheme 2021" (ESOP 2021). The ESOP 2021 allows the issue of options to employees of the Company and its subsidiaries. Each option comprises one underlying equity share. Under the Scheme, a maximum of 6,267,000 Options can be granted.

As per the Scheme, the Nomination and Remuneration Committee (NRC) grants the options to the employees deemed eligible subject to fulfillment of such eligibility criteria(s) as may be specified in the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 ("SEBI (SBEB) Regulations") and/or as may be determined by NRC from time to time. Exercise Price for the purpose of grant of options shall be as decided by the NRC, subject to a minimum of the face value per share. The vesting of an option would also be subject to the terms and conditions as may be stipulated by the NRC from time to time including but not limited to performance of the stock of the Company, performance of the employees, their continued employment with the Company / its subsidiaries, as applicable. The vesting period shall commence any time after the expiry of one year from the date of the grant of the options to the employee and shall end over a maximum period of 7 years from the date of the grant of the options. The options could vest in tranches. The exercise period may commence from the date of vesting and the vested options would be eligible to be exercised on the vesting date itself or any time after vesting in terms of the ESOP Scheme. The options will lapse if not exercised within the specified exercise period. The number of stock options and terms of the same made available to employees (including the vesting period) could vary at the discretion of the NRC.

Employee stock options will be settled by delivery of shares.


B (i) The detail of fair market value and the exercise price is as given below:

Particulars	ESOP 2014					
Date of grant	10 Nov 16	22 May 18	09 Nov 18	07 Feb 19	08 Aug 19	08 Aug 19
Fair market value of option at grant date (Rs)	232.48	298.55	220.74	181.62	48.45	94.94
Fair market value of share at grant date (Rs)	240.15	306.81	231.85	187.00	102.35	102.35
Exercise price (Rs)	10.00	10.00	10.00	10.00	110.68	10.00
No. of options	165,400	55,000	25,000	47,000	30,000	141,800

Particulars	ESOP 2021	ESOP 2021	ESOP 2021	ESOP 2021	ESOP 2021	ESOP 2021
Date of grant	11 Jun 21	11 Jun 21	09 Nov 21	09 Nov 21	10 Feb 22	10 Feb 22
Vesting basis	Time based	Performance based	Time based	Performance based	Time based	Performance based
Fair market value of option at grant date (Rs)	108.77	46.04	169.57	76.02	160.10	95.06
Fair market value of share at grant date (Rs)	197.65	197.65	261.85	261.85	249.70	249.70
Exercise price (Rs)	130.00	130.00	130.00	130.00	130.00	130.00
No. of options	780,000	1,820,000	138,000	322,000	73,500	171,500

Particulars	ESOP 2021	ESOP 2021	ESOP 2021	ESOP 2021	ESOP 2021	ESOP 2021
Date of grant	26 May 22	26 May 22	10 Aug 22	10 Aug 22	10 Nov 22	10 Nov 22
Vesting basis	Time based	Performance based	Time based	Performance based	Time based	Performance based
Fair market value of option at grant date (Rs)	188.05	122.56	196.35	123.93	211.54	133.51
Fair market value of share at grant date (Rs)	275.55	275.55	284.20	284.20	298.85	298.85
Exercise price (Rs)	130.00	130.00	130.00	130.00	130.00	130.00
No. of options	6,000	14,000	34,500	80,500	34,500	80,500

Particulars	ESOP 2021	ESOP 2021	ESOP 2021	ESOP 2021	ESOP 2021	ESOP 2021
Date of grant	09 Feb 23	09 Feb 23	01 Apr 23	01 Apr 23	09 Aug 23	09 Aug 23
Vesting basis	Time based	Performance based	Time based	Performance based	Time based	Performance based
Fair market value of option at grant date (Rs)	200.22	139.21	139.90	58.82	208.12	64.08
Fair market value of share at grant date (Rs)	287.45	287.45	262.45	262.45	338.10	338.10
Exercise price (Rs)	130.00	130.00	200.00	200.00	200.00	200.00
No. of options	18,000	42,000	150,000	350,000	12,000	28,000



Vy.

38 Share-based payments (Contd..)

Particulars	ESOP 2021	ESOP 2021
Date of grant	09.Nov.23	09.Nov.23
Vesting basis	Time based	Performance based
Fair market value of option at grant date (Rs.)	241.10	66.75
Fair market value of share at grant date (Rs.)	373.10	373.10
Exercise price (Rs.)	200.00	200.00
No. of options	66,000	154,000

(ii) The assumptions used for calculating fair value of the ESOPs granted during the year ended 31 March 2025 are as below:

The company has not issued any grants during the year

The assumptions used for calculating fair value of the ESOPs granted during the year ended 31 March 2024 are as below:

Time based options

The Black-Scholes option pricing model has been used for computing the weighted average fair value considering the following inputs:

Assumptions	ESOP 2021	ESOP 2021	ESOP 2021
Grant date	01.Apr.23	09.Aug.23	09.Nov.23
Risk free interest rate	7.15% to 7.18%	7.15% to 7.19%	7.23% to 7.29%
Expected life	1 to 6 years	1 to 6 years	1 to 6 years
Expected annual volatility of shares	34.47% to 38.44%	34.86% to 37.94%	34.53% to 37.27%
Expected dividend yield	0.00%	0.00%	0.00%

Performance based options

The Monte Carlo Simulation model has been used for computing the weighted average fair value considering the following inputs:

Assumptions	ESOP 2021	ESOP 2021	ESOP 2021
Grant date	01.Apr.23	09.Aug.23	09.Nov.23
Volume weighted average price of stock as on grant date	286.53	296.83	272.08
Risk free interest rate	7.17%	7.15%	7.22%
Expected life	5.50 years	5.14 years	4.89 years
Expected annual volatility of shares	35.89%	36.79%	37.01%

C Employee stock options details as on the Balance Sheet date are as follows:

Particulars	Year ended 31 March 2025		Year ended 31 March 2024	
	Options (Numbers)	Weighted average exercise price per option (Rs.)	Options (Numbers)	Weighted average exercise price per option (Rs.)
Option outstanding at the beginning of the year:				
- ESOP 2014	36,380	93.02	68,300	54.22
- ESOP 2021	3,472,025	144.69	3,092,080	130.00
Granted during the year:				
- ESOP 2014	-	-	-	-
- ESOP 2021	-	-	760,000	200.00
Forfeited during the year:				
- ESOP 2014	-	-	5,220	10.00
- ESOP 2021	162,255	130.00	5,130	130.00
Exercised during the year:				
- ESOP 2014	32,040	10.00	25,700	10.00
- ESOP 2021	93,643	130.00	147,925	130.00
Lapsed during the year:				
- ESOP 2014	-	-	1,000	10.00
- ESOP 2021	225	139.71	227,000	139.71
Options outstanding at the end of the year:				
- ESOP 2014	4,340	779.77	36,380	93.02
- ESOP 2021	3,215,902	144.69	3,472,025	144.69
Options exercisable at the end of the year:				
- ESOP 2014	4,340	779.77	36,380	93.02
- ESOP 2021	383,491	130.00	383,491	130.00

* Options available for grant are as under:

- ESOP 2021: 2,581,950 as at 31 March 2025 (as at 31 March 2024: 2,581,950)


** The above figure include options granted to employees of the subsidiaries.

The weighted average share price at the date of exercise for share options exercised during the year ended 31 March 2025 is Rs. 390.42 (31 March 2024: Rs. 334.24).

The options outstanding at the end of the reporting period has exercise price in the range of Rs. 10 to Rs. 200 (31 March 2024: Rs. 10 to Rs. 200) and weighted average remaining contractual life of 3.40 years (31 March 2024: 4.82 years).

For details of amendments made to ESOP Scheme 2021, refer note 51.

D For details of expense recognised in statement of profit and loss please refer note 27 and for details of movement in share options outstanding account refer note 16.2



39 Financial instruments

A Accounting classification and fair values

The following table shows the carrying amount and fair values of the financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

As at 31 March 2025	Carrying amount	Fair value			
		Level 1	Level 2	Level 3	Total
Financial assets measured at fair value					
FVTPL					
Investments in unquoted equity instruments - other funds	49.53	-	-	49.53	49.53
Investments in mutual fund (quoted)	20.50	20.50	-	-	20.50
Financial assets not measured at fair value					
Amortised cost					
Loans	26.96	-	-	-	-
Trade receivable	4,008.96	-	-	-	-
Cash and cash equivalents (including other bank balances)	3,476.97	-	-	-	-
Other financial assets	754.53	-	-	-	-
	8,337.45				
Fair value through retained earnings					
Gross obligation on written put option	634.00	-	-	634.00	634.00
Financial liabilities not measured at fair value					
Amortised cost					
Loans and Borrowings (including short-term borrowings)	10,022.31	-	10,078.42	-	10,078.42
Trade payables	3,342.59	-	-	-	-
Other financial liabilities	557.86	-	-	-	-
Obligation towards forward liability	1,401.34	-	-	-	-
	15,958.10				

As at 31 March 2024	Carrying amount	Fair value			
		Level 1	Level 2	Level 3	Total
Financial assets measured at fair value					
FVTPL					
Investments in unquoted equity instruments - other funds	50.72	-	-	50.72	50.72
Investments in mutual fund (quoted)	18.93	18.93	-	-	18.93
Financial assets not measured at fair value					
Amortised cost					
Loans	19.43	-	-	-	-
Trade receivable	2,940.26	-	-	-	-
Cash and cash equivalents (including other bank balances)	3,030.73	-	-	-	-
Other financial assets	553.95	-	-	-	-
	6,614.02				
Fair value through retained earnings					
Gross obligation on written put option	1,060.00	-	-	1,060.00	1,060.00
Financial liabilities measured at fair value					
FVTPL					
Contingent consideration	27.82	-	-	27.82	27.82
Financial liabilities not measured at fair value					
Amortised cost					
Loans and Borrowings (including short-term borrowings)	6,727.57	-	6,776.86	-	6,776.86
Trade payables	2,810.65	-	-	-	-
Other financial liabilities	520.87	-	-	-	-
	11,174.73				

Refer note 18 for details related to pledge of financial assets

There have been no transfers among Level 1, Level 2 and Level 3 during each of the years presented above.



39 Financial instruments (Contd..)

Financial instruments measured at fair value (Level 2 and Level 3):

Type	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value measurement
Unquoted equity instruments - funds	Recent completed transaction in the underlying investment	1. Price per share 2. Qualitative factors on operating performance vis a vis budgets 3. Regulatory factors	Not applicable
Contingent consideration	In determining the fair value, the risk adjusted revenues for forward 12 months' revenue from the acquisition date was estimated using a Monte Carlo Simulation model. The undiscounted contingent consideration payable based on expected revenue is then present valued using the risk adjusted discount rate to arrive at the fair value of contingent consideration.	1. Risk adjusted revenues for forward 12 months' revenue from the acquisition date 2. Risk adjusted discount rate: 11.7%	The estimated fair value would increase / (decrease) if: • the future revenues are higher (lower); • the discount rate is lower (higher);
Gross obligation towards written put option	In determining the fair value the equity value for forward 72 months' from the acquisition date was estimated using a Monte Carlo Simulation model	1. Risk adjusted discount rate: 9.6% 2. Revenue growth rate: 6% to 57% 3. Terminal growth rate: 6%	The estimated fair value would increase / (decrease) if: • the future revenues are higher (lower); • the discount rate is lower (higher);

The Group's borrowings have been contracted at floating rates of interest, which are reset at short intervals. Accordingly, the carrying value of such borrowings (including interest accrued but not due) approximates fair value.

Details of assets and liabilities considered under Level 3 classification

Particulars	Investment in equity instruments
Balance as at 1 April 2023	51.62
Redemption of investment during the year	(0.90)
Balance as at 31 March 2024	50.72
Redemption of investment during the year	(1.19)
Balance as at 31 March 2025	49.53

As at 31 March 2025 and 31 March 2024, a one percentage point change in the unobservable inputs used in fair valuation of Level 3 assets does not have a significant impact in its value.


Particulars	Gross obligation on written put option
Balance as at 1 April 2023	970.00
Change in fair value (Refer note 16.6)	90.00
Balance as at 31 March 2024	1,060.00
Recognition of put obligation (Refer note 16.6)	608.00
Subsequent remeasurement through retained earnings for gross obligation towards put option (Refer note 16.6)	26.00
Derecognition of liability towards put option (Refer note 16.6)	(1,060.00)
Balance as at 31 March 2025	634.00

There is a wide range of possible fair value measurements for the valuation of exercise price of written-put option included in Level 3 of fair value hierarchy and the amount considered above represents the estimate of the fair value within that range.

Details of Profit and Loss account

Particulars	Contingent consideration, Gross obligation on Put option and Obligation towards forward Liability
Assumed in a business combination (refer note 45.2)	26.30
Interest accrued in 'finance cost'	1.52
For the year ended 31 March 2024	27.82
Remeasurement of contingent consideration	(27.82)
Interest on forward liability	53.88
For the year ended 31 March 2025	53.88

Reasonably possible change in the unobservable inputs used in fair valuation of Level 3 assets does not have a significant impact in its value.



40 Financial risk management

The Group's principal financial liabilities, comprise loans and borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the Group's operations and to provide guarantees to support its operations. The Group's principal financial assets include loans, trade and other receivables, and cash and short-term deposits that derive directly from its operations. The Group's activities expose it to a variety of financial risks: credit risk, liquidity risk and market risks which may adversely impact the fair value of its financial instruments.

(i) Risk management framework

The Group has a risk management policy which covers risks associated with the financial assets and liabilities. The focus of risk management committee is to assess the unpredictability of the financial environment and to mitigate potential adverse effects on the financial performance of the Group.

(ii) Credit risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Group is exposed to the credit risk from its trade receivables, security deposit, investments, cash and cash equivalents, bank deposits and loans. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses in financial assets.

a) Trade and other receivables

Trade receivables are unsecured comprise a widespread customer base. Group assesses the credit quality of the customer, taking into account its financial position, past experience and other factors. Individual risk limits are set for patients without medical aid insurance. Services to customers without medical aid insurance are settled in cash or using major credit cards on discharge date as far as possible. Credit Guarantees insurance is not purchased.

The Group has used a practical expedient by computing the expected credit loss allowance for trade receivables based on a provision matrix. The provision matrix takes into account historical credit loss experience and adjusted for forward looking information wherever required. The expected credit loss allowance is based on the ageing of the receivables from their expected period of recovery and the rates as derived as per the trend of trade receivable ageing of previous years.

1. The Provision matrix at the end of the reporting period is as follows:-

Category	As at	
	31 March 2025	31 March 2024
Less than 1 year	4% to 38%	4% to 38%
1-2 years	47% to 63%	47% to 63%
2-3 years	78% to 90%	78% to 90%
More than 3 years	100%	100%

2. The provision details of the trade receivable is given below.

Movement in the expected credit loss allowance	For the year ended	
	31 March 2025	31 March 2024
Balance at beginning of the year	700.91	475.30
Additional provision during the year (refer note 30)	204.24	229.93
Written-off during the year *	(97.27)	(4.32)
Balance at end of the year (refer note 13)	807.88	700.91

* The receivables that are written off would still be subject to enforcement activities for recovery of amounts due.

No single customer accounted for more than 10% of the revenue as of 31 March 2025 and 31 March 2024. There is no significant concentration of credit risk.

Details of geographic concentration of revenue is included in note 36 to the financial statements

b) Investments and cash deposits

The Group limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Group does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors.

(iii) Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they become due. The Group manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due.

The Group's corporate treasury department is responsible for liquidity, funding as well as settlement management. In addition, processes and policies related to such risks are overseen by senior management. Also refer note 41.

The table below provides details regarding the contractual maturities of significant financial liabilities as at 31 March 2025 and 31 March 2024.

Particulars	As at 31 March 2025					
	Total	Less than 1 year	1-2 years	2-3 years	3-4 years	More than 4 years
Borrowings *	11,294.89	4,020.81	1,254.64	1,239.37	1,059.05	3,721.02
Lease liabilities	14,309.92	1,341.86	1,205.97	1,162.75	1,121.48	9,477.86
Trade payables	3,342.59	3,342.59	-	-	-	-
Other financial liabilities	2,593.20	1,959.20	-	-	-	634.00

Particulars	As at 31 March 2024					
	Total	Less than 1 year	1-2 years	2-3 years	3-4 years	More than 4 years
Borrowings *	6,804.89	1,874.56	896.32	852.53	876.81	2,304.67
Lease liabilities	9,969.93	951.27	842.31	851.73	804.61	6,520.01
Trade payables	2,810.65	2,810.65	-	-	-	-
Other financial liabilities	1,636.51	1,636.51	-	-	-	-

* In respect of borrowings which are repayable with variable rate of interest, principal amount as per the repayment schedule is considered for disclosure of contractual maturities.



40 Financial risk management (continued)**(iv) Market risk:**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices, such as foreign exchange rates, interest rates and equity prices.

(a) Foreign currency risk

The Group's exchange risk arises mainly from its foreign currency borrowings. As a result, depreciation of Indian rupee relative to these foreign currencies will have a significant impact on the financial performance of the Group. The exchange rate between the Indian rupee and these foreign currencies has changed substantially in recent periods and may continue to fluctuate substantially in the future.

(i) Exchange rates exposure are managed within approved policy parameters. The following table presents unhedged foreign currency risk from financial instruments as of 31 March 2025 and 31 March 2024

As at 31 March 2025	Rupee equivalent of foreign currency amounts		
	US \$	Euro	Total
Particulars			
Assets			
Cash and cash equivalents	2.35	-	2.35
Liabilities			
Borrowings	193.13	-	193.13
Lease liabilities	247.06	-	247.06
Trade payable	17.12	1.19	18.31
Net assets / (liabilities)	(454.96)	(1.19)	(456.15)

As at 31 March 2024	Rupee equivalent of foreign currency amounts		
	US \$	Euro	Total
Particulars			
Assets			
Cash and cash equivalents	16.45	-	16.45
Liabilities			
Borrowings	80.47	133.87	214.34
Lease liabilities	284.27	-	284.27
Trade payable	10.74	0.35	11.09
Net assets / (liabilities)	(359.03)	(134.22)	(493.25)

(ii) Sensitivity analysis

The sensitivity of profit or loss to changes in exchange rates arises mainly from foreign currency denominated financial instruments

Particulars	Impact on profit or (loss) before tax		Impact on equity, net of tax	
	As at	As at	As at	As at
	31 March 2025	31 March 2024	31 March 2025	31 March 2024
Sensitivity				
Rs:USD - Increase by 1%	(4.55)	(3.59)	(3.40)	(2.69)
Rs:USD - Decrease by 1%	4.55	3.59	3.40	2.69
Rs:Euro - Increase by 1%	(0.01)	(1.34)	(0.01)	(1.34)
Rs:Euro - Decrease by 1%	0.01	1.34	0.01	1.34

(b) Cash flow and fair value interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's debt obligations with floating interest rates and investments. Such risks are overseen by the Group's corporate treasury department as well as senior management.

(i) Interest rate risk exposure


The exposure of the Group's borrowing to interest rate changes at the end of the reporting period are as follows:

Particulars	As at	As at
	31 March 2025	31 March 2024
Variable rate long term borrowings including current maturities	6,791.84	5,320.31
Total borrowings	6,791.84	5,320.31

(ii) Sensitivity analysis

Every 1% increase or decrease in interest rate does not have material impact to statement of profit and loss and other components of equity

Particulars	Impact on profit or (loss) before tax		Impact on equity, net of tax	
	As at	As at	As at	As at
	31 March 2025	31 March 2024	31 March 2025	31 March 2024
Sensitivity				
1% increase in interest rate	(67.92)	(53.20)	(50.82)	(43.85)
1% decrease in interest rate	67.92	53.20	50.82	43.85



41 Capital management

The Group manages its capital to ensure that entities in the Group will be able to continue as going concerns while maximising the return to stakeholders through the optimisation of the debt and equity balance. The capital structure of the Group consists of net debt (borrowings offset by cash and bank balances) and total equity of the Group.

The capital structure is as follows:


Particulars	As at	As at
	31 March 2025	31 March 2024
Total equity attributable to the equity share holders of the Group	9,224.41	8,257.80
As percentage of total capital	58%	69%
Total loans and borrowings	10,022.31	6,727.57
Cash and cash equivalents and other bank balances	3,476.97	3,030.73
Net loans & borrowings	6,545.34	3,696.84
As a percentage of total capital	42%	31%
Total capital (loans and borrowings and equity)	15,769.75	11,954.64

42 Due to Micro, Small and Medium Enterprises (refer note 22)

The Ministry of Micro, Small and Medium Enterprises has issued an office memorandum dated 26 August 2008 which recommends that the Micro and Small Enterprises should mention in their correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum. Accordingly, the disclosure in respect of the amounts payable to such enterprises as at 31 March 2025 and 31 March 2024 have been made in the financial statements based on information received and available with the group. Further in view of the management, the impact of interest, if any, that may be payable in accordance with the provisions of the Micro, Small and Medium Enterprises Development Act, 2006 ('The MSMED Act') is not expected to be material. The group has not received any claim for interest from any supplier.

Particulars	As at 31 March 2025	As at 31 March 2024
The amounts remaining unpaid to micro and small suppliers as at the end of the year	41.38	62.12
Principal	41.38	62.09
Interest	-	0.03
The amount of interest paid by the buyer under MSMED Act	-	-
The amount of payments made to micro and small suppliers beyond the appointed day during the accounting year	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act.	-	-
The amount of interest accrued and remaining unpaid at the end of each accounting year	-	0.03
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under the MSMED Act	-	-

All trade payables are 'current.' The Group's exposure to currency and liquidity risks related to trade payable is disclosed in note 40.



43 Related Party Disclosure

Transactions and balances between the Company and its subsidiaries which are related parties of the Company have been eliminated and are not disclosed in this note.

A Details of related parties:


Description of relationship	Names of related parties
Parent entity	Aceso Company Pte Ltd
Intermediate Parent entity	Aceso Investment Holding Pte Ltd
Ultimate Parent entity	CVC Capital Partners Asia V L P
Joint venture	Advanced Molecular Imaging Limited, Kenya
Fellow subsidiary	Irelia Sports India Private Limited
Key management personnel (KMP)	Whole-time director
	Dr. B S Ajaikumar - Executive Chairman
	Meghraj Arvindrao Gore (upto 09 February 2025)
	Anjali Rossi Ajaikumar
	Non-executive directors
	Amit Soni
	Siddharth Patel
	Independent Directors
	Geeta Mathur
	Rajagopalan Raghavan
Jeyandran Venugopal	
Pradip M Kanakia	
Abhay Havaldar (upto 1 April 2023)	
Rajiv Malhiwal (with effect from 25 May 2023)	
Other Key Managerial Personnel	
Meghraj Arvindrao Gore - Chief Executive Officer (also Whole-time Director upto 09 February 2025)	
Srinivasa V Raghavan - Chief Financial Officer (upto 20 August 2023)	
Ruby Ritolia - Chief Financial Officer (with effect from 21 August 2023)	
Sunu Manuel- Company Secretary	
Relatives of KMP	Anjali Ajaikumar Rossi, daughter of Dr. B S Ajaikumar -Whole-time Director
Company entity in which KMP / Relatives of KMP can exercise control / significant influence	JSS Bharath Charitable Trust Sada Sarada Tumor & Research Institute B C C H I Trust HCG Foundation GHA Global Healthcare Academy Private Limited Gutti Malnad Hospital LLP International Human Development and Upliftment Academy (Trust)

Transactions and balances between the Company and its subsidiaries which are related parties of the Company, have been eliminated and are not disclosed.

B Details of related party transactions during the year:

Particulars	Year ended 31 March 2025	Year ended 31 March 2024
Sale of medical and non-medical items		
- Sada Sarada Tumor & Research Institute	4.92	3.71
Income from medical services		
- HCG Foundation	15.98	3.39
- Sada Sarada Tumor & Research Institute	6.22	6.23
Purchase of Capital Asset		
- Sada Sarada Tumor & Research Institute	18.20	1.70
Promotion and Marketing of Offline and Online courses		
GHA Global Healthcare Academy Private Limited	19.17	10.67
CSR contribution to		
- International Human Development and Upliftment Academy (Trust)	10.77	4.87
Promotion and Marketing of offline and online courses		
- Irelia Sports India Private Limited	9.46	4.86
Short-term employee benefits to:		
- Dr. B S Ajaikumar (refer note 44)	60.00	48.97
- Meghraj Arvindrao Gore (refer note 44)	33.08	33.08
- Anjali Ajaikumar Rossi (refer note 44)	15.00	15.00
- Ruby Ritolia	14.50	10.88
- Srinivasa Raghavan	-	4.64
- Sunu Manuel	5.62	5.60

V4.



43 Related Party Disclosure (Contd..)

Particulars	Year ended 31 March 2025	Year ended 31 March 2024
Post-employment benefits to:		
- Dr. B S Ajaikumar	0.55	0.91
- Meghraj Arvindrao Gore	0.56	0.47
- Anjali Ajaikumar Rossi	0.83	0.27
- Srinivasa Raghavan	-	(0.01)
- Ruby Ritohia	0.22	0.05
- Sunu Manuel	0.24	0.15
Share based payments to:		
- Srinivasa Raghavan	-	1.40
- Sunu Manuel	0.50	0.62
- Meghraj Arvindrao Gore	12.10	15.14
- Ruby Ritohia	12.71	5.26
Sitting fees to Directors		
- Rajiv Mahwal	2.36	2.00
- Pradip M. Kanakia	2.36	2.36
- Geeta Mathur	2.36	2.36
- Rajagopalan Raghavan	2.36	2.36
Transactions and balances between the company and its subsidiaries which are related parties of the company, have been eliminated and are not disclosed		

C Details of related party balances outstanding:

Balances outstanding as at	31 March 2025	31 March 2024
Trade receivables		
- Sada Sarada Tumor & Research Institute	0.26	2.94
- B C C H J Trust	0.01	0.01
- HCG Foundation	6.61	3.21
- Guttu Malnad Hospital LLP	1.35	1.35
Receivable from related parties - Other Financial Assets (current)		
- Sada Sarada Tumor & Research Institute	7.77	6.98
Security deposits (refundable) with		
- Guttu Malnad Hospital LLP	3.50	3.50
Accrued employee benefits - Other financial liabilities (current)		
- Dr. B S Ajaikumar	37.04	10.67
- Meghraj Arvindrao Gore	13.03	12.99
- Ms. Anjali Ajaikumar Rossi	3.95	3.49
- Ruby Ritohia	4.84	3.28
- Sunu Manuel	0.68	0.66
Provision for post-employment benefits:		
- Dr. B S Ajaikumar	3.76	3.34
- Meghraj Arvindrao Gore	1.89	1.14
- Ms. Anjali Ajaikumar Rossi	2.47	1.72
- Ruby Ritohia	0.34	0.11
- Sunu Manuel	2.02	1.86
Other payable to related party - Other Financial Liability - current		
- Sada Sarada Tumor & Research Institute	-	1.70
Trade payables		
- HCG Foundation	0.17	0.06

All transactions with the related parties are priced at arm's length basis and resulting outstanding balances are to be settled as per the terms agreed. None of the balances are secured.

44 Managerial remuneration:


For the financial year ended 31 March 2025

The managerial remuneration for the year ended 31 March 2025 was approved by the Nomination and Remuneration Committee, the Board of Directors and is in accordance with the limits prescribed under Section 197 read with Schedule V to the Companies Act, 2013 considering the approval of the Shareholders of the Company through special resolution obtained on 25 June 2023 in respect of remuneration to Dr. B S Ajaikumar, Meghraj Arvindrao Gore and Anjali Ajaikumar Rossi.

During the year ended 31 March 2025, Aceso Company Pte Ltd, the promoter of the Company, through its parent Aceso Investment Holdings Pte Ltd ("AIHPL") has proposed making bonus payment directly to certain key managerial personnel and employees of the Company ("Identified Employees") without the Company being party to such arrangement subject to such conditions as AIHPL may determine in sole discretion, as consideration for the Identified Employees performing their duties and enhancement of shareholder value. Bonus will be paid by AIHPL to the KMPs and Identified Employees after deducting the applicable taxes. There is no financial obligation on the Company pursuant to this payout. The proposed transaction was duly approved by the Board of Directors of the Company in their meeting held on 21 February 2025 and by shareholders of the Company through postal ballot on 27 April 2025 pursuant to the provisions of Regulation 26(6) and other relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For the financial previous year ended 31 March 2024

The managerial remuneration for the previous year ended 31 March 2024 was approved by the Nomination and Remuneration Committee, the Board of Directors and is in accordance with the limits prescribed under Section 197 read with Schedule V to the Companies Act, 2013 considering the approval of the Shareholders of the Company through special resolution obtained on 25 June 2023 in respect of remuneration to Dr. B S Ajaikumar, Meghraj Arvindrao Gore and Anjali Ajaikumar Rossi.



Vy.

45 Business Combinations**45.1 Vizag Hospital And Cancer Research Centre Private Limited (VHCRPL)**

During the current year ended 31 March 2025, pursuant to the Share Purchase Agreement dated 28 June 2024 with Vizag Hospital And Cancer Research Centre Private Limited (VHCRPL) and its shareholders, the Company has acquired 51% equity shares of VHCRPL on 01 October 2024 for a consideration of Rs. 2,063.2 millions and acquired the control of VHCRPL from 02 October 2024. Further as per the terms of the agreement the Company has committed to acquire an additional 34% of equity share capital of VHCRPL for a consideration of Rs. 1,540 million (approx.) which is payable within 18 months from the date of first closing (i.e 01 October 2024). Based on the purchase price allocation done by the management, an amount of Rs. 2,070.14 million was recorded as Goodwill. The consideration for the balance 15% of equity share capital will be determined as per the terms of the shareholder agreement. With respect to this remaining 15%, the selling shareholder of VHCRPL has a put option to sell its stake to the Company, which can be exercised within 12 months post the expiry of 54 months from the First Closing Date. The gross obligation towards put option is initially measured at the fair value as on 01 October 2024 as Rs. 608 million with corresponding impact in retained earnings. Further, the subsequent changes in carrying amount of the gross obligation towards put option amounting to Rs. 26 million is routed through the retained earnings and an amount of Rs. 634 million is recognised under other current liabilities as at 31 March 2025.

The acquisition contributed revenue of Rs. 501.74 million and profit after tax of Rs. 48.84 million for the period between the acquisition date and 31 March 2025. Further, for the period from 01 April 2024 till the date of acquisition the acquiree would have contributed revenue of Rs. 599.75 million and profit after tax of Rs. 137.17 million if the business combination occurred on 01 April 2024.

a) Business combination

This transaction has been accounted under Ind AS 103 'Business Combinations' accordingly the fair value of the assets acquired, liabilities assumed has been recognised as on the date on which control was obtained. The difference between purchase consideration, NCI and net assets has been recognised as goodwill.

b) Identifiable assets and liabilities assumed

Particulars	Rs. in Million
Fair value of consideration transferred	
Cash consideration for 51% stake	2,063.20
Forward Liability for additional 34% stake	1,347.00
Total (A)	3,410.20
Assets acquired	
Property, plant and equipment	921.20
Right-of-use assets	9.73
Intangible assets: Non-compete	13.00
Other intangible assets - Brand	277.00
Inventories	7.40
Other assets	522.25
Cash and cash equivalents	91.25
Total assets acquired (B)	1,841.83
Liabilities assumed	
Lease liabilities	10.84
Trade payables and other liabilities	254.37
Total liabilities assumed (C)	265.21
Net assets acquired [D = (B-C)]	1,576.62
Non Controlling interest (E)	236.56
Goodwill (A+E -D)	2,070.14
Cash consideration for 51% stake	2,063.20
Less: Cash and cash equivalents	(91.25)
Payment for acquisition of business (net of cash acquired)	1,971.95

c) Valuation Method

i) Property, plant and equipment. Sale Comparable Method under Market Approach and Cost Approach of Valuation is adopted to estimate Fair Value of immovable assets in the form of land and structures built over it. Replacement Cost method under Cost approach of valuation is employed for estimation of Fair Value of movable assets in the form of plant, machinery and equipment.

ii) Brand: The brand has been valued using the Income Approach -Relief from royalty method. The income approach is a valuation method whereby the present value of future benefits associated with ownership of the asset are quantified. The estimated future benefits that accrue to the owner are discounted or capitalized at a rate appropriate for the risks associated with those future benefits.

iii) Goodwill is attributable to the synergies expected to be achieved from this acquisition. Goodwill is not tax deductible.


d) The Company incurred Rs. 25.9 million towards legal and professional fees in respect of business acquisition which was charged off in the statement of profit and loss as other expenses.

45.2 Business acquisition of SRJ Health Care Private Limited and Amrsh Oncology Services Private Limited

During the previous year ended 31 March 2024, pursuant to the Business Transfer Agreements ("BTA") with SRJ Health Care Private Limited and Amrsh Oncology Services Private Limited, the Company acquired their comprehensive cancer care centre and Radiation unit / centre respectively in Indore on a slump sale basis on 3 October 2023. As per the terms of the BTA, the Company had paid upfront consideration aggregating to Rs. 450 million. The BTA also provides for contingent consideration to be paid after 12 months from the date of acquisition amounting to a maximum of Rs. 160 million. The amount of contingent consideration was dependent upon the achievement of financial performance of the business acquired.

Date of business combination - The acquisition was completed on 3 October 2023

The acquisition had contributed revenue of Rs. 121.82 million and loss after tax of Rs. 20.97 million for the period between the acquisition date and 31 March 2024. Statutory financial statements of the acquiree were not available for the period from 01 April 2023 till the date of acquisition and hence it was impracticable to disclose revenue and profit or loss of the acquiree for the current reporting period as if the business combination had occurred on 01 April 2023.



45.2 Business acquisition of SRJ Health Care Private Limited and Amrsh Oncology Services Private Limited (Contd..)

a) Business combination

The above transaction qualified as a business combination as per Ind AS 103 - "Business Combinations" and was accounted by applying the acquisition method wherein identifiable assets acquired, liabilities assumed were fair valued against the fair value of the consideration transferred and the resultant goodwill recognised

b) Identifiable assets and liabilities assumed

Particulars	Rs. in Million
Fair value of consideration transferred	
Cash consideration	450.00
Fair Value of Contingent Consideration	26.30
Total (A)	476.30
Assets acquired	
Property, plant and equipment	50.71
Right-of-use assets	251.17
Intangible assets: Non-compete	13.00
Other intangible assets	0.21
Inventories	4.31
Other assets	2.45
Total assets acquired (B)	321.85
Liabilities assumed	
Lease liabilities	228.04
Trade payables and other liabilities	34.40
Total liabilities assumed (C)	262.44
Net assets acquired [D = (B-C)]	59.41
Goodwill (A-D)	416.89


- i) Property, plant and equipment: Cost approach (reproduction cost method) has been adopted to estimate the fair value of Property, plant and equipment.
- ii) Intangible assets: Non-compete has been valued using the Lost profit Method. The projected revenues and operating expenses are estimated in a "With" and "Without" scenario for the non- compete agreement, and the differential between the profits from the two scenarios serves as the basis for estimating fair value. Non-compete has useful life of 3 years.
- iii) Goodwill is attributable to the synergies expected to be achieved from this acquisition. Goodwill is not tax deductible.
- iv) Trade receivables: Fair value and the gross contractual amounts due of the acquired trade receivables as at the acquisition date is Rs. 0.42 million
- v) Contingent consideration: Contingent consideration is linked to pre-determined EBITDA margin (at 14.25%) over the forward 12 months revenue in excess of Rs. 316 million from the acquisition date. Contingent consideration is capped to a maximum of Rs. 160 million. During the year ended 31 March 2024, the management has determined the fair value of contingent consideration as at the acquisition date of Rs. 26.30 million. In determining the fair value, the risk adjusted revenues for forward 12 months' revenue from the acquisition date was estimated using a Monte Carlo Simulation model. The undiscounted contingent consideration payable based on expected revenue is then present valued using the discount rate of 11.7 % to arrive at the fair value of contingent consideration. During the year ended 31 March 2024, interest of Rs. 1.52 million has been accrued as a result of which the contingent consideration has increased to Rs. 27.82 million as at 31 March 2024. During the year ended 31 March 2025, the Management remeasured the fair value of contingent consideration payable as Nil. Consequently, the contingent consideration of Rs. 27.8 million (including interest accounted) has been written back in Other income during the year ended 31 March 2025.
- c) During the year ended 31 March 2024, the Company incurred Rs. 11.72 million towards legal and professional fees in respect of this business acquisition which has been charged-off in the Statement of profit and loss as Other expenses.

45.3 Acquisition of Nagpur Cancer Hospital & Research Institute Private Limited

During the previous year ended 31 March 2024, pursuant to the Share Purchase Agreement with Nagpur Cancer Hospital & Research Institute Private Limited ("NCHRI") and its shareholders, the Company acquired 100% equity shares of NCHRI on 22 August 2023 for a consideration of Rs. 141 million. Hence, NCHRI became wholly owned subsidiary of the Company.

NCHRI has constructed a hospital building on the land leased by Nagpur Improvement Trust, a planning authority for the city of Nagpur established by the Government of Maharashtra. The Group has been operating comprehensive cancer centre of NCHRI under a medical services arrangement, through its subsidiary - HCG NCHRI Oncology LLP. With the acquisition of NCHRI, the Group has obtained control over its assets.

The above transaction does not qualify as a business combination as per Ind AS 103 - "Business Combinations". Accordingly, the management has accounted this acquisition as an asset acquisition. The acquisition cost of the group of assets (including transaction costs of Rs. 7.94 million towards legal and professional fees in respect of this acquisition) is allocated to the individual assets based on their relative fair values.



Vy.

45.3 Acquisition of Nagpur Cancer Hospital & Research Institute Private Limited (Contd..)

Allocation of acquisition cost to the identified assets and liabilities as at 22 August 2023:

Particulars	Rs. in Million
Acquisition cost allocable	
Cash consideration for acquisition for shares in NCHRI	141.00
Oncology LLP	(88.00)
Add: Settlement of pre-existing receivable balances of the Group from NCHRI	313.30
Add: Transaction costs in respect of this acquisition	7.94
Total (A)	374.24
Assets acquired	
Property, plant and equipment	508.50
Trade receivables	167.23
Cash and cash equivalents	25.65
Other assets	41.37
Total assets acquired (B)	742.75
Liabilities assumed	
Borrowings	336.17
Trade payables and other liabilities	32.34
Total liabilities assumed (C)	368.51
Allocated costs to net assets (D) = (B-C)	374.24

Property, plant and equipment: Depreciated Replacement Cost method is adopted to estimate the fair value of Property, plant and equipment.

Trade receivables: Fair value of the acquired trade receivables as at 22 August 2023 is Rs. 167.23 million. The trade receivables comprise gross contractual amounts due of Rs. 228.23 million, of which Rs. 60.90 million was expected to be uncollectable.

Settlement of pre-existing relationship


As mentioned above, the Group and NCHRI were parties to a long-term service contract under Medical Services Agreement pursuant to which the Group provided medical services to NCHRI. The pre-existing relationship was effectively terminated when the Group acquired NCHRI. The Group concluded that there was no gain / loss on termination of the above mentioned agreement. The balances recoverable from / payable to NCHRI have been settled at recorded amount with no gain / loss.

45.4 The Board of Directors, in their meeting held on 9 November 2024, had approved the following arrangements between the Company and HCG NCHRI Oncology LLP (a wholly owned subsidiary of the Company), effective 1 December 2024:

1. Transfer of the diagnostic business by the brand name of Trista and the PET-CT & Cyclotron business located at Chennai from the Company to HCG NCHRI Oncology LLP by way of a slump sale; and
2. Transfer of the oncology hospital business at Nagpur from HCG NCHRI Oncology LLP to the Company by way of a slump sale.

The slump sale agreements have been accounted for as per the guidance contained in Indian Accounting Standards (IND AS) 103 Business Combination, in the standalone financial statements of the respective entities.

Further, based on the management assessment of the reasonable certainty of availability of future profits in HCG NCHRI Oncology LLP, the Group has recognized a deferred tax credit of Rs. 141 million on the brought forward business losses and unabsorbed depreciation, during the year ended 31 March 2025.



Vy.

HealthCare Global Enterprises Limited
Notes to the consolidated financial statements for the year ended 31 March 2025 (continued)

46 Subsidiaries, Associate & Joint venture

46.1 Details of the Group's subsidiaries at the end of the reporting period are as follows

Name of the subsidiary	Note	Place of incorporation and operation	Proportion of ownership interest and voting power held by the Group	
			As at 31 March 2025	As at 31 March 2024
HCG Medi-Surge Hospitals Private Limited		India	74.00%	74.00%
Mahad Hospital & Institute of Oncology Private Limited		India	70.25%	70.25%
HealthCare Global Sentinel Multi Speciality Hospital Private Limited		India	100.00%	100.00%
Niruja Product Development and Research Private Limited		India	100.00%	100.00%
BACC Healthcare Private Limited		India	100.00%	100.00%
HealthCare Divan Chand Imaging LLP		India	75.00%	75.00%
HCG Oncology Hospitals LLP (formerly, Apex HCG Oncology Hospitals LLP)		India	100.00%	100.00%
HCG Oncology LLP		India	74.00%	74.00%
HCG NCTRI Oncology LLP	16.6 (ii)	India	100.00%	100.00%
Nagpur Cancer Hospital & Research Institute Private Limited	45.3	India	100.00%	100.00%
HCG Manavata Oncology LLP	a	India	51.00%	51.00%
HCG Kolkata Cancer Care LLP (formerly known as HCG EKO Oncology LLP)	16.6 (ii)	India	100.00%	100.00%
HCG (Mauritius) Private Limited		Mauritius	100.00%	100.00%
Healthcare Global (Africa) Private Limited		Mauritius	100.00%	100.00%
Healthcare Global (Uganda) Private Limited, Uganda		Uganda	100.00%	100.00%
Healthcare Global (Kenya) Private Limited, Kenya		Kenya	100.00%	100.00%
Healthcare Global (Tanzania) Private Limited, Tanzania		Tanzania	100.00%	100.00%
Cancer Care Kenya Limited, Kenya		Kenya	81.63%	81.63%
Suehirayu Health Care Solutions Limited		India	78.60%	78.60%
HCG Rajkot Hospitals LLP (formerly known as HCG Sun Hospitals LLP)		India	100.00%	100.00%
Vizag Hospital And Cancer Research Centre Private Limited	45.1	India	51.00%	0.00%

The principal activity of all the above mentioned subsidiaries is providing Healthcare services.

Note a: The directors of the Company assessed whether or not the Group has control over the above mentioned entities based on whether the Group has the practical ability to direct the relevant activities of such entities unilaterally. Based on such assessment, the directors concluded that the Group has sufficient management rights to unilaterally direct the relevant activities of such entities and therefore the Group has control.

46.2 Interests in Joint venture


Name of the Joint Venture	Place of incorporation	Proportion of ownership interest and voting power held by the Group	
		As at 31 March 2025	As at 31 March 2024
Advanced Molecular Imaging Limited	Kenya	50.00%	50.00%
Investments in Advanced Molecular Imaging Limited is held by HealthCare Global (Kenya) Private Limited. The principal activity of the Joint Venture is to provide Healthcare services.			

Rs. in million

	Year ended	
	31 March 2025	31 March 2024
Carrying amount of Group's interest in the Joint Venture accounted for using the equity method	43.09	33.60
Group's share of profit (loss) from continuing operations	7.71	3.88
Group's share of other comprehensive income	1.78	1.21
Group's share of total comprehensive income	9.49	5.09

* The management has set materiality at ten percent of the annual consolidated turnover, as per the last audited financial statements of the Company. Based on the materiality set by the management, the joint venture of the Group is not material and hence summarised financial information of the joint venture is not presented.

Ug.



HealthCare Global Enterprises Limited

Notes to the consolidated financial statements for the year ended 31 March 2025 (continued)

46.3 Statement of net assets, profit and loss and other comprehensive income attributable to owners and non-controlling interest:

Name of the entity	Net assets (total assets minus total liabilities) as at 31 March 2025		Share in profit or loss for the year ended 31 March 2025		Share in other comprehensive income for the year ended 31 March 2025		Share of total comprehensive income for the year ended 31 March 2025	
	As % of consolidated net assets	Rs. Million	As % of consolidated profit or loss	Rs. Million	As % of consolidated Other comprehensive Income	Rs. Million	As % of consolidated total comprehensive Income	Rs. Million
(I) Parent								
HealthCare Global Enterprises Limited *	71.98%	11,913.21	10.69%	30.19	16.55%	2.98	11.04%	33.17
2) Subsidiaries								
a) Indian								
HCG Medi-Surge Hospitals Private Limited	5.41%	894.98	42.73%	120.67	(5.05)%	(0.91)	39.87%	119.76
HCG NCHRI Oncology LLP	0.94%	156.07	65.35%	184.53	(16.99)%	(3.06)	60.41%	181.47
Vizag Hospital and Cancer Research Centre Private Limited	5.04%	834.61	17.30%	48.84	13.10%	2.36	17.05%	51.20
Nagpur Cancer Hospital & Research Institute Private Limited	0.02%	3.90	3.83%	10.82	0.00%	-	3.60%	10.82
Nirjuga Product Development and Research Private Limited	(1.40)%	(231.87)	0.00%	-	(1.78)%	(0.32)	0.00%	-
Mahad Hospital & Institute of Oncology Private Limited	0.50%	82.19	3.04%	8.57	0.00%	-	2.75%	8.25
HealthCare Global Sembl Multi Speciality Hospital Private Limited	0.01%	1.43	0.00%	-	0.00%	-	0.00%	-
Healthcare Dwan Chand Imaging LLP	0.14%	23.75	(0.02)%	(0.05)	0.00%	-	(0.02)%	(0.05)
BACC Healthcare Private Limited	1.23%	203.21	(23.57)%	(66.55)	4.05%	0.73	(21.91)%	(65.82)
HCG Oncology Hospitals LLP (formerly, Apex HCG Oncology Hospitals LLP)	(0.57)%	(94.22)	(54.64)%	(154.29)	(0.56)%	(0.10)	(51.40)%	(154.39)
HCG Oncology LLP	(0.78)%	(129.41)	13.41%	37.86	(0.61)%	(0.11)	12.57%	37.75
HCG Kolkata Cancer Care LLP (formerly known as HCG EKO Oncology LLP)	(1.86)%	(307.66)	(26.44)%	(74.67)	(0.72)%	(0.13)	(24.90)%	(74.80)
HCG Manavata Oncology LLP	1.83%	302.85	(17.30)%	(48.86)	0.61%	0.11	(16.23)%	(48.75)
HCG Rajkot Hospitals LLP (formerly known as HCG Sun Hospitals LLP)	0.89%	147.23	(3.02)%	(8.54)	(0.06)%	(0.01)	(2.85)%	(8.55)
Suehirayu Health Care Solutions Limited	(0.13)%	(21.49)	11.93%	33.70	(1.89)%	(0.34)	11.11%	33.36
b) Foreign								
HCG (Mauritius) Pvt. Ltd	2.48%	409.87	0.09%	0.26	184.34%	33.20	11.14%	33.46
Healthcare Global (Africa) Private Limited	4.80%	795.11	(0.39)%	(1.10)	0.00%	-	(0.37)%	(1.10)
Healthcare Global (Uganda) Private Limited	(0.00)%	(0.65)	0.09%	0.26	(0.33)%	(0.06)	0.07%	0.20
Healthcare Global (Kenya) Private Limited	3.65%	603.84	2.68%	7.56	8.44%	1.52	3.02%	9.08
Cancer Care Kenya Limited	1.51%	249.33	36.37%	102.69	(119.38)%	(21.50)	27.03%	81.19
Healthcare Global (Tanzania) Private Limited	(0.03)%	(5.43)	(0.52)%	(1.47)	0.00%	-	(0.49)%	(1.47)
c) Joint venture								
Advanced Molecular Imaging Limited	0.26%	43.09	2.73%	7.71	9.88%	1.78	3.16%	9.49
d) Non-controlling interest	4.08%	676.05	15.67%	44.24	10.38%	1.87	15.35%	46.11
Total	100.00%	16,549.99	100.00%	282.37	100.00%	18.01	100.00%	300.38
Adjustment arising on consolidation		(6,649.53)		243.80		-		243.80
Total		9,900.46		526.17		18.01		544.18

* before consolidation adjustments

U4.




HealthCare Global Enterprises Limited

Notes to the consolidated financial statements for the year ended 31 March 2025 (continued)

46.4 Statement of net assets, profit and loss and other comprehensive income attributable to owners and non-controlling interest:

Name of the entity	Net assets (total assets minus total liabilities) as at 31 March 2024		Share of profit or loss for the year ended 31 March 2024		Other Comprehensive Income for the year ended 31 March 2024		Share of total comprehensive income for the year ended 31 March 2024	
	As % of consolidated net assets	Rs. Million	As % of consolidated profit or loss	Rs. Million	As % of consolidated Other comprehensive income	Rs. Million	As % of consolidated total comprehensive income	Rs. Million
1) Parent								
HealthCare Global Enterprises Limited *	79.34%	11,885.85	339.05%	339.59	62.85%	(2.91)	352.43%	336.68
2) Subsidiaries								
a) Indian								
HCG Medi-Surge Hospitals Private Limited	5.18%	775.30	244.35%	244.74	19.01%	(0.88)	255.27%	243.86
HCG NCHRI Oncology LLP	(0.28%)	(41.56)	(14.92%)	(14.94)	9.29%	(0.43)	(16.09%)	(15.37)
Nagpur Cancer Hospital & Research Institute Private Limited	(0.05%)	(6.92)	5.40%	5.41	0.00%	-	5.66%	5.41
Niruja Product Development and Research Private Limited	(1.55%)	(231.87)	0.00%	-	0.00%	-	0.00%	-
Mahad Hospital & Institute of Oncology Private Limited	0.49%	74.01	9.27%	9.28	2.81%	(0.13)	9.58%	9.15
HealthCare Global Semblit Multi Speciality Hospital Private Limited	0.01%	1.43	0.00%	-	0.00%	-	0.00%	-
Healthcare Diwan Chand Imaging LLP	0.16%	23.80	(0.07%)	(0.07)	0.00%	-	(0.07%)	(0.07)
BACC Healthcare Private Limited	1.80%	269.03	(11.85%)	(11.87)	11.88%	(0.55)	(13.00%)	(12.42)
HCG Oncology Hospitals LLP (formerly, Apex HCG Oncology Hospitals LLP)	0.40%	60.17	(115.27%)	(115.45)	3.89%	(0.18)	(121.04%)	(115.63)
HCG Oncology LLP	(1.12%)	(167.16)	10.08%	10.10	11.66%	(0.54)	10.01%	9.56
HCG Kolkata Cancer Care LLP (formerly known as HCG EKO Oncology LLP)	(1.55%)	(232.86)	(196.71%)	(197.02)	4.10%	(0.19)	(206.44%)	(197.21)
HCG Manavata Oncology LLP	2.35%	351.58	(88.47%)	(88.61)	1.73%	(0.08)	(92.84%)	(88.69)
HCG Rajkot Hospitals LLP (formerly known as HCG Sun Hospitals LLP)	1.04%	155.78	(26.98%)	(27.02)	5.83%	(0.27)	(28.57%)	(27.29)
Suchitray Health Care Solutions Limited	(0.37%)	(54.85)	25.69%	25.73	5.62%	(0.26)	26.66%	25.47
b) Foreign								
HCG (Mauritius) Pvt. Ltd	2.37%	354.46	0.86%	0.86	(66.52%)	3.08	4.12%	3.94
Healthcare Global (Africa) Private Limited	4.76%	712.99	(1.48%)	(1.48)	0.00%	-	(1.55%)	(1.48)
Healthcare Global (Uganda) Private Limited	(0.01%)	(0.83)	(0.29%)	(0.29)	0.00%	-	(0.30%)	(0.29)
Healthcare Global (Kenya) Private Limited	3.47%	519.39	0.84%	0.84	21.38%	(0.99)	(0.16%)	(0.15)
Cancer Care Kenya Limited	0.73%	110.05	(13.97%)	(13.99)	25.05%	(1.16)	(15.86%)	(15.15)
Healthcare Global (Tanzania) Private Limited	(0.03%)	(4.17)	(1.32%)	(1.32)	0.00%	-	(1.38%)	(1.32)
d) Joint venture								
Advanced Molecular Imaging Limited	0.22%	33.60	3.87%	3.88	(26.13%)	1.21	5.33%	5.09
e) Non-controlling interest								
	2.63%	393.38	(68.10%)	(68.21)	7.56%	(0.35)	(71.77%)	(68.56)
Total	100.00%	14,980.60	100.00%	100.16	100.00%	(4.63)	100.00%	95.53
Adjustment arising on consolidation		(6,329.42)		313.18		-		313.18
Total		8,651.18		413.34		(4.63)		408.71

*before consolidation adjustments



127

47 Investments, loans, guarantees and security

(a) The Group has made redeemed / investment in the following companies during the year ended 31 March 2025

Investment in equity instruments	As at 1 April 2024	Invested during the year	Sold / (redeemed) during the year	As a 31 March 2025
Investment in other companies / funds				
Zoctr Health Private Limited #	7.64	-	-	7.64
International Stemcell Services Limited	5.61	-	-	5.61
Epigeneres Biotech Private Limited #	10.00	-	-	10.00
Niramai Health Analytix Private Limited	35.86	-	-	35.86
Anthill Venture Capital Advisors LLP	9.10	-	(1.19)	7.91

Fair value of the investments is Nil

(b) The Group has made redeemed / investment in the following companies during the year ended 31 March 2024

Investment in equity instruments	As at 1 April 2023	Invested during the year	Sold / (redeemed) during the year	As a 31 March 2024
Investment in other companies / funds				
Zoctr Health Private Limited #	7.64	-	-	7.64
International Stemcell Services Limited	5.61	-	-	5.61
Epigeneres Biotech Private Limited #	10.00	-	-	10.00
Niramai Health Analytix Private Limited	35.86	-	-	35.86
Anthill Venture Capital Advisors LLP	10.00	-	(0.90)	9.10

Fair value of the investments is Nil

48 Ind AS 115- Revenue from contracts with customers

Contract balances

(a) Receivables

Trade receivables (including unbilled revenue)

	As at 31 March 2025	As a 31 March 2024
Trade receivables (including unbilled revenue)	4,008.96	2,940.26

b) The Group does not have any contract asset as at 31 March 2025 and 31 March 2024.

c) The contract liability amount from contracts with customers is given below :

Advance from customers . Refer note 20

167.58 181.87

Revenue recognised in the reporting period that was included in the contract liability balance

181.87 241.50

d) Revenue dis-aggregation as per the industry vertical and geographies has been included in note 23, revenue from operations.



Vy.

49 Other statutory information of the Company


- (i) The Group does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.
- (ii) The Group does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (iii) The Group has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (iv) During the year ended 31 March 2025, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Group to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Group or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- (v) During the year ended 31 March 2025, no funds have been received by the Group from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Group shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Party or provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries.
- (vi) The Group has not made any private placement of shares or fully or partly convertible debentures during the year.
- (vii) The Group does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year ended 31 March 2025 in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- (viii) The Group is not declared as willful defaulter by any bank or financial institution (as defined under the Companies Act, 2013) or consortium thereof or other lender in accordance with the guidelines on willful defaulters issued by the Reserve Bank of India.
- (ix) The Group has complied with the number of layers for its holding in downstream companies prescribed under clause (87) of section 2 of the Companies Act, 2013 read with the Companies (Restriction on number of Layers) Rules, 2017.
- (x) The Group did not have any material transactions with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the year ended 31 March 2025.
- (xi) The Group has not revalued any of its Property, Plant and Equipment (including Right-of-Use Assets) during the year ended 31 March 2025.

50 During the year ended 31 March 2025, the Board of Directors of the Company had approved share purchase agreement (SPA) dated 23 February 2025 between Aceso Company Pte. Ltd. ("Seller"), Hector Asia Holdings II Pte. Ltd. ("Purchaser 1") and KIA EBT II Scheme 1 ("Purchaser 2") (Purchaser 1 and Purchaser 2 collectively, "Purchasers") and the Company, for the sale of upto 54% of the diluted voting share capital of the Company from Seller to the Purchasers. Hector Asia Holdings II Pte. Ltd. is an affiliate of funds, vehicles and/or entities managed and/or advised by Kohlberg Kravis Roberts & Co. L.P., which is an indirect subsidiary of KKR & Co. Inc. Pursuant to the SPA, the Purchasers have agreed to purchase from the Seller, the equity shares of the Company held by Seller equivalent up to 54.00% of the diluted voting share capital of the Company in two tranches, with an upfront acquisition of 51.00% of the diluted voting share capital of the Company at a price of Rs.445 per share and transfer the control of the Company from Seller to Purchasers. This transaction is subject to various regulatory approvals.

51 During the year ended 31 March 2025, Board of Directors of the Company has approved amendment to the ESOP 2021 Scheme at their meeting held on 21 February 2025 and the same was approved by the shareholders of the Company through postal ballot on 27 April 2025. This provides an option to surrender up to maximum of 16,19,741 employee stock options ("Relevant ESOPs") held by option holders ("Relevant Option Holder") that have vested prior to or immediately following the Trade Sale (as defined in the grant letter) and provide them cash for such amount which is the lower of (i) the per share price at which a shareholder has a right to tender shares in any mandatory public offer prevailing at the time less exercise price of the Option, and (ii) per share value of Rs.495 less the exercise price of the Option in accordance with the terms of the ESOP letters / agreement to be entered into between the Company and the Relevant Option Holder. The impact of this post balance sheet event has not been given effect in this consolidated financial statements for the year ended 31 March 2025.

The accompanying notes are an integral part of these consolidated financial statements.

As per our reports of even date attached
for BSR & Co. LLP
Chartered Accountants
Firm's registration number: 101248W W -100022


Vikash Gupta
Partner
Membership number: 064597

Place : Bengaluru
Date : 24 May 2025


Dr. B.S. Ajaikumar
Executive Chairman
DIN: 00713779
Place : Bengaluru
Date : 24 May 2025


Ruby Ritolia
Chief Financial Officer
Place : Bengaluru
Date : 24 May 2025

for and on behalf of the Board of Directors of
HealthCare Global Enterprises Limited


Meghraj Arvindrao Gore
Chief Executive Officer
Place : Bengaluru
Date : 24 May 2025


Sanu Manuel
Company Secretary
Place : Bengaluru
Date : 24 May 2025


Anjali Ajaikumar Rossi
Director
DIN: 08057112
Place : Geneva
Date : 24 May 2025



Quality Checks :	Completed
Spelling / Diction / Comparison	<input type="checkbox"/>
Indexing / Pagination / Paras	<input type="checkbox"/>
Calculation / Arithmetical accountancy /	<input type="checkbox"/>
Rounding off errors	<input type="checkbox"/>
Done by :	
Name & Designation	
Signature & Date	
Engagement Partner	
Project Code	